N-benzyl heterocyclic carboxamides

ABSTRACT

The present invention relates to N-benzyl heterocyclic carboxamides derivatives or their thiocarboxamides derivatives, their process of preparation, their use as fungicide, particularly in the form of compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.

CROSS REFERENCE TO RELATED APPLICATION(S)

The present application is a 35 U.S.C. §371 national phase conversion of PCT/EP2011/068288 filed on Oct. 20, 2011, which claims priority to European Application No. 10356028.0 filed on Oct. 21, 2010 and U.S. Provisional Application No. 61/421,033 filed on Dec. 8, 2010. Applicants claim priority to the foregoing patent applications. The PCT International Application was published in the English language.

The present invention relates to N-benzyl heterocyclic carboxamides derivatives or their thiocarboxamides derivatives, their process of preparation, their use as fungicides, particularly in the form of compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.

In publication J. Korean Agric. Chem. Soc. (1992), 35(2), 87-91 [CAN 117:207009] certain fungicidal amides are generically embraced in the following formula:

wherein R can represent a hydrogen atom, a chlorine atom, a methyl group or a methoxy group. However, there is no disclosure or suggestion in these documents of any such derivative wherein the 3-substituent of the pyrazolyl group can represent a dihalogenomethyl group. Furthermore, there is no disclosure or suggestion in this document of any compound including an alkyl group, an alkoxy group or a C₄-C₇-cycloalkyl group linked to the nitrogen atom of the carboxamide residue.

In international patent application WO-2009/024342 certain fungicidal pyrazole-4-carboxylic acid amides are generically embraced in a broad disclosure of numerous compounds of the following formula:

Wherein R₁ can represent an alkyl group, R₂ can represent a halogenoalkyl group, R₁₅ can represent a hydrogen atom or a cyclopropyl group, R₃ or R₄ can represent various substituents among which an alkyl group, a haloalkyl group and the like, and B can represent a phenyl group, a naphthyl group or a mono or bicyclic heteroaromatic ring system. However, there is no disclosure or suggestion in this document of any such derivative wherein the 5-substituent of the pyrazolyl group can represent a halogen atom. Furthermore, there is no disclosure or suggestion in this document of any compound including an alkyl group, an alkoxy group or a C₄-C₇-cycloalkyl group linked to the nitrogen atom of the carboxamide residue.

In international patent application CN1188764 certain fungicidal pyrazole derivatives are generically embraced in a broad disclosure of numerous compounds of the following formula:

Wherein R₁ or R₂ can represent an alkyl group or a halogenoalkyl group, X can represent a direct bond, R₃ can represent various substituents among which a chlorine atom, R₄ can represent various substituents among which an oxygen or a sulfur atom, Y and Z can represent a direct bond, and Q can represent various groups among which a substituted benzyl group. However, there is no disclosure or suggestion in this document of any compound including an alkyl group, an alkoxy group or a C₄-C₇-cycloalkyl group linked to the nitrogen atom of the carboxamide residue. Furthermore, there is no explicit disclosure or suggestion to select in this document of any such derivative wherein the pyrazolyl group can represent a 1-methyl-3-(difluoro or dichloro)methyl-5-(chloro or fluoro)-4-pyrazolyl group.

In international patent applications WO-2006/120224 and WO-2007/087906, certain amide derivatives are generically embraced in a broad disclosure of numerous compounds of the following formula:

wherein A can represent a carbo-linked, partially saturated or unsaturated, 5-membered heterocyclyl group that can be substituted, Z can represent a(n) (un)substituted cycloalkyl group and B can represent a(n) (un)substituted benzyl group or a substituted 2-pyridylmethylene group. However, there is no disclosure or suggestion in these documents of any compound including a hydrogen atom, an alkyl group or an alkoxy group linked to the nitrogen atom of the carboxamide residue. Furthermore, there is no explicit disclosure or suggestion to select in these documents of any such derivative wherein A can represent a 1-methyl-3-(difluoro or dichloro)methyl-5-(chloro or fluoro)-4-pyrazolyl group.

In international patent applications WO-2009/016221, certain amide derivatives are generically embraced in a broad disclosure of numerous compounds of the following formula:

wherein A can represent a carbo-linked, partially saturated or unsaturated, 5-membered heterocyclyl group that can be substituted, T can be O or S, Z¹ can represent a(n) (un)substituted cycloalkyl group, Z² and Z³ can represent a hydrogen atom, a C₁-C₈-alkyl among other groups, and B can represent a naphthyl group or a bicyclic heteroaromatic group. However, there is no disclosure or suggestion in this document of any compound including a hydrogen atom, an alkyl group or an alkoxy group linked to the nitrogen atom of the carboxamide residue. Moreover, there is no disclosure or suggestion in this document of any compound where B is to be replaced by a phenyl group or a 2-pyridyl group. Furthermore, there is no explicit disclosure or suggestion to select in this document of any such derivative wherein A can represent a 1-methyl-3-(difluoro or dichloro)methyl-5-(chloro or fluoro)-4-pyrazolyl group.

It is always of high interest in agriculture to use novel pesticide compounds in order to avoid or to control the development of resistant strains to the active ingredients. It is also of high interest to use novel compounds being more active than those already known, with the aim of decreasing the amounts of active compound to be used, whilst at the same time maintaining effectiveness at least equivalent to the already known compounds. We have now found a new family of compounds that possess the above mentioned effects or advantages.

Accordingly, the present invention provides derivatives of formula (I)

wherein

-   -   Y represents CR⁵ or N;     -   T represents O or S;     -   X¹ and X² which can be the same or different, represent a         chlorine or a fluorine atom;     -   Z¹ represents a hydrogen atom, substituted or non substituted         C₁-C₈-alkyl; substituted or non substituted C₁-C₈-alkoxy;         substituted or non substituted C₂-C₈-alkenyl; substituted or non         substituted C₂-C₈-alkynyl; substituted or non substituted         C₄-C₇-cycloalkyl; substituted or non substituted         C₃-C₇-cycloalkyl-C₁-C₈-alkyl; substituted or non substituted         3-oxetanyl; or substituted or non substituted 3-thietanyl;     -   Z² and Z³, which can be the same or different, represent a         hydrogen atom; substituted or non substituted C₁-C₈-alkyl;         substituted or non substituted C₂-C₈-alkenyl; substituted or non         substituted C₂-C₈-alkynyl; cyano; isonitrile; nitro; a halogen         atom; substituted or non substituted C₁-C₈-alkoxy; substituted         or non substituted C₂-C₈-alkenyloxy; substituted or non         substituted C₂-C₈-alkynyloxy; substituted or non substituted         C₃-C₇-cycloalkyl; substituted or non substituted         C₁-C₈-alkylsulfanyl; substituted or non substituted         C₁-C₈-alkylsulfonyl; substituted or non substituted         C₁-C₈-alkylsulfinyl; amino; substituted or non substituted C₁-C₈         alkylamino; substituted or non substituted di-C₁-C₈-alkylamino;         substituted or non substituted C₁-C₈-alkoxycarbonyl; substituted         or non substituted C₁-C₈-alkylcarbamoyl; substituted or non         substituted di-C₁-C₈-alkylcarbamoyl; or substituted or non         substituted N—C₁-C₈-alkyl-C₁-C₈-alkoxy-carbamoyl; or     -   Z³ and R¹ together with the consecutive carbon atoms to which         they are linked form a substituted or non substituted 5-, 6- or         7-membered, partly saturated, carbo- or hetero-cycle comprising         up to 3 heteroatoms and Z² is as herein described; or     -   Z² and Z³ together with the carbon atom to which they are linked         form a substituted or non substituted C₃-C₇ cycloalkyl;     -   R¹, R², R³, R⁴ and R⁵, which can be the same or different,         represent a hydrogen atom; a halogen atom; nitro; cyano;         isonitrile; hydroxyl; sulfanyl; amino; pentafluoro-λ⁶-sulfanyl;         substituted or non substituted C₁-C₈-alkyl; C₁-C₈-halogenoalkyl         comprising up to 9 halogen atoms which can be the same or         different; substituted or non substituted C₁-C₈-alkylamino;         substituted or non substituted di-C₁-C₈-alkylamino; substituted         or non substituted C₁-C₈ alkoxy; C₁-C₈-halogenoalkoxy comprising         up to 9 halogen atoms which can be the same or different;         C₁-C₈-alkoxy-C₁-C₈-alkyl; substituted or non substituted         C₁-C₈-alkylsulfanyl; C₁-C₈-halogenoalkylsulfanyl comprising up         to 9 halogen atoms which can be the same or different;         substituted or non substituted C₂-C₈-alkenyl;         C₂-C₈-halogenoalkenyl comprising up to 9 halogen atoms which can         be the same or different; substituted or non substituted         C₂-C₈-alkynyl; C₂-C₈-halogenoalkynyl comprising up to 9 halogen         atoms which can be the same or different; substituted or non         substituted C₂-C₈-alkenyloxy; C₂-C₈-halogenoalkenyloxy         comprising up to 9 halogen atoms which can be the same or         different; substituted or non substituted C₂-C₈-alkynyloxy;         C₂-C₈-halogenoalkynyloxy comprising up to 9 halogen atoms which         can be the same or different; substituted or non substituted         C₃-C₇-cycloalkyl; C₃-C₇-halogenocycloalkyl comprising up to 9         halogen atoms which can be the same or different; substituted or         non substituted C₃-C₇-cycloalkyl-C₁-C₈-alkyl; substituted or non         substituted C₃-C₇-cycloalkyl-C₂-C₈-alkenyl; substituted or non         substituted C₃-C₇-cycloalkyl-C₂-C₈-alkynyl; substituted or non         substituted C₃-C₇-cycloalkyl-C₃-C₇-cycloalkyl; substituted or         non substituted C₁-C₈-alkyl-C₃-C₇-cycloalkyl; formyl; formyloxy;         formylamino; carboxy; carbamoyl; N-hydroxycarbamoyl; carbamate;         (hydroxyimino)-C₁-C₈-alkyl; substituted or non substituted         C₁-C₈-alkylcarbonyl; C₁-C₈-halogenoalkylcarbonyl comprising up         to 9 halogen atoms which can be the same or different;         substituted or non substituted C₁-C₈-alkylcarbamoyl; substituted         or non substituted di-C₁-C₈-alkylcarbamoyl; N-(substituted or         non substituted C₁-C₈ alkyloxy)carbamoyl; substituted or non         substituted C₁-C₈-alkoxycarbamoyl; N-(substituted or non         substituted C₁-C₈-alkyl)-(substituted or non substituted         C₁-C₈-alkoxy)-carbamoyl; substituted or non substituted         C₁-C₈-alkoxycarbonyl; C₁-C₈-halogenoalkoxycarbonyl comprising up         to 9 halogen atoms which can be the same or different;         substituted or non substituted C₁-C₈-alkylaminocarbonyl;         di-substituted or non substituted C₁-C₈-alkylaminocarbonyl;         substituted or non substituted C₁-C₈-alkylcarbonyloxy;         C₁-C₈-halogenoalkylcarbonyloxy comprising up to 9 halogen atoms         which can be the same or different; substituted or non         substituted C₁-C₈-alkylcarbonylamino;         C₁-C₈-halogenoalkylcarbonylamino comprising up to 9 halogen         atoms which can be the same or different; substituted or non         substituted C₁-C₈-alkylaminocarbonyloxy; substituted or non         substituted di-C₁-C₈-alkylaminocarbonyloxy; substituted or non         substituted C₁-C₈ alkyloxycarbonyloxy; substituted or non         substituted C₁-C₈-alkylsulfinyl; C₁-C₈-halogenoalkylsulfinyl         comprising up to 9 halogen atoms which can be the same or         different; substituted or non substituted C₁-C₈-alkylsulfonyl;         C₁-C₈-halogenoalkylsulfonyl comprising up to 9 halogen atoms         which can be the same or different; substituted or non         substituted C₁-C₈ alkoxyimino; (C₁-C₈-alkoxyimino)-C₁-C₈-alkyl;         substituted or non substituted         (C₁-C₈-alkenyloxyimino)-C₁-C₈-alkyl;         (C₁-C₈-alkynyloxyimino)-C₁-C₈-alkyl; a         (benzyloxyimino)-C₁-C₈-alkyl; tri(substituted or non substituted         C₁-C₈-alkyl)silyl; tri(substituted or non substituted         C₁-C₈-alkyl)silyl-C₁-C₈-alkyl; benzyloxy which can be         substituted by up to 5 groups Q; benzylsulfanyl which can be         substituted by up to 5 groups Q; benzylamino which can be         substituted by up to 5 groups Q; aryl which can be substituted         by up to 7 groups Q; aryloxy which can be substituted by up to 7         groups Q; arylamino which can be substituted by up to 7 groups         Q; arylsulfanyl which can be substituted by up to 7 groups Q;         aryl-C₁-C₈alkyl which can be substituted by up to 7 groups Q;         aryl-C₂-C₈-alkenyl which can be substituted by up to 7 groups Q;         aryl-C₂-C₈-alkynyl which can be substituted by up to 7 groups Q;         pyridinyl which can be substituted by up to 4 groups Q;         pyridinyloxy which can be substituted by up to 4 groups Q;         aryl-C₃-C₇-cycloalkyl which can be substituted by up to 7 groups         Q; or         -   Two vicinal substituents R together with the consecutive             carbon atoms to which they are linked form a substituted or             non substituted 5- or 6-membered, saturated, carbo- or             hetero-cycle comprising up to 3 heteroatoms and the other             substituents R are as herein-described; or     -   R¹ and Z³ together with the consecutive carbon atoms to which         they are linked form a substituted or non substituted 5-, 6- or         7-membered, partly saturated, carbo- or hetero-cycle comprising         up to 3 heteroatoms, and R² to R⁵ are as herein-described;     -   Q, which can be the same or different, represents a halogen         atom; cyano; nitro; C₁-C₈-alkyl; C₁-C₈-alkoxy;         C₁-C₈-alkylsulfanyl; C₁-C₈-halogenoalkyl comprising up to 9         halogen atoms which can be the same or different;         C₁-C₈-halogenoalkoxy comprising up to 9 halogen atoms which can         be the same or different; tri(C₁-C₈)alkylsilyl or         tri(C₁-C₈)alkylsilyl-C₁-C₈-alkyl;         as well as salts, N-oxides, metal complexes, metalloid complexes         and optically active or geometric isomers thereof.

Unless indicated otherwise, a group or a substituent that is substituted according to the invention can be substituted by one or more of the following groups or atoms: a halogen atom; nitro; hydroxyl; cyano; isonitrile; amino; thio; a pentafluoro-λ⁶-sulfanyl group; formyl; formyloxy; formylamino; carbamoyl; N-hydroxycarbamoyl; carbamate; (hydroxyimino)-C₁-C₆-alkyl; C₁-C₈-alkyl; a tri(C₁-C₈-alkyl)silyl; C₃-C₈-cycloalkyl; C₁-C₈-halogenoalkyl having 1 to 5 halogen atoms; a C₃-C₈-halogenocycloalkyl having 1 to 5 halogen atoms; C₂-C₈-alkenyl; C₂-C₈-alkynyl; C₂-C₈-alkenyloxy; C₂-C₈-alkynyloxy; C₁-C₈-alkylamino; di-C₁-C₈-alkylamino; C₁-C₈-alkoxy; C₁-C₈-halogenoalkoxy having 1 to 5 halogen atoms; C₁-C₈-alkylsulfanyl; C₁-C₈-halogenoalkylsulfanyl having 1 to 5 halogen atoms; C₂-C₈-alkenyloxy; C₂-C₈-halogenoalkenylwry having 1 to 5 halogen atoms; C₃-C₈-alkynyloxy; C₃-C₈-halogenoalkynyloxy having 1 to 5 halogen atoms; C₁-C₈-alkylcarbonyl; C₁-C₈-halogenoalkylcarbonyl having 1 to 5 halogen atoms; C₁-C₈-alkylcarbamoyl; di-C₁-C₈-alkylcarbamoyl; N—C₁-C₈-alkyloxycarbamoyl; C₁-C₈-alkoxycarbamoyl; N—C₁-C₈-alkyl-C₁-C₈-alkoxycarbamoyl; C₁-C₈-alkoxycarbonyl; C₁-C₈-halogenoalkoxycarbonyl having 1 to 5 halogen atoms; C₁-C₈-alkylcarbonyloxy; C₁-C₈-halogenoalkylcarbonyloxy having 1 to 5 halogen atoms; C₁-C₈-alkylcarbonylamino; C₁-C₈-halogenoalkylcarbonylamino having 1 to 5 halogen atoms; C₁-C₈-alkylaminocarbonyloxy; di-C₁-C₈-alkylaminocarbonyloxy; C₁-C₈-alkyloxycarbonyloxy; C₁-C₈-alkylsulfanyl; C₁-C₈-halogenoalkylsulfanyl having 1 to 5 halogen atoms; C₁-C₈-alkylsulfinyl; C₁-C₈-halogenoalkylsulfinyl having 1 to 5 halogen atoms; C₁-C₈-alkylsulfonyl; C₁-C₈-halogenoalkyl-sulfonyl having 1 to 5 halogen atoms; C₁-C₈-alkylaminosulfamoyl; di-C₁-C₈-alkylaminosulfamoyl; (C₁-C₆-alkoxyimino)-C₁-C₆-alkyl; (C₁-C₆-alkenyloxyimino)-C₁-C₆-alkyl; (C₁-C₆-alkynyloxyimino)-C₁-C₆-alkyl; 2-oxopyrrolidin-1-yl; (benzyloxyimino)-C₁-C₆-alkyl; C₁-C₈-alkoxyalkyl; C₁-C₈-halogenoalkoxyalkyl having 1 to 5 halogen atoms; benzyloxy; benzylsulfanyl; benzylamino; aryloxy; arylsulfanyl or arylamino.

Any of the compounds according to the invention can exist as one or more stereoisomers depending on the number of stereogenic units (as defined by the IUPAC rules) in the compound. The invention thus relates equally to all the stereoisomers, and to the mixtures of all the possible stereoisomers, in all proportions. The stereoisomers can be separated according to the methods that are known per se by the man ordinary skilled in the art.

According to the invention, the following generic terms are generally used with the following meanings:

-   -   halogen means fluorine, chlorine, bromine or iodine;     -   heteroatom can be nitrogen, oxygen or sulfur;     -   any alkyl, alkenyl or alkynyl group can be linear or branched;     -   the term “aryl” means phenyl or naphthyl, optionally         substituted;     -   In the case of an amino group or the amino moiety of any other         amino-comprising group, substituted by two substituents that can         be the same or different, the two substituents together with the         nitrogen atom to which they are linked can form a heterocyclyl         group, preferably a 5- to 7-membered heterocyclyl group, that         can be substituted or that can include other hetero atoms, for         example a morpholino or piperidinyl group.

Preferred compounds of formula (I) according to the invention are those wherein Y represents CR⁵.

Other preferred compounds of formula (I) according to the invention are those wherein Y represents N.

Other preferred compounds of formula (I) according to the invention are those wherein T represents 0.

Other preferred compounds of formula (I) according to the invention are those wherein X¹ represents a fluorine atom.

Other preferred compounds of formula (I) according to the invention are those wherein X² represents a fluorine atom.

Other preferred compounds of formula (I) according to the invention are those wherein Z¹ represents a hydrogen atom.

Other preferred compounds of formula (I) according to the invention are those wherein Z¹ represents a methyl or an ethyl.

Other preferred compounds of formula (I) according to the invention are those wherein Z¹ represents a unsubstituted cyclobutyl.

Other preferred compounds of formula (I) according to the invention are those wherein Z² and Z³ independently represent a hydrogen atom or a methyl.

More preferred compounds of formula (I) according to the invention are those wherein Z² represents a hydrogen atom and Z³ represents a hydrogen atom or a methyl.

Other preferred compounds of formula (I) according to the invention are those wherein R¹, R², R³, R⁴ and R⁵, which can be the same or different, represent a hydrogen atom; a halogen atom; substituted or non substituted C₁-C₈-alkyl; C₁-C₈-halogenoalkyl comprising up to 9 halogen atoms which can be the same or different; substituted or non substituted C₃-C₇-cycloalkyl; tri(C₁-C₈-alkyl)silyl; or substituted or non substituted C₁-C₈-alkylsulfanyl.

More preferred compounds of formula (I) according to the invention are those wherein the substituent R¹ represents a halogen atom; C₁-C₈-alkyl; C₁-C₈-halogenoalkyl comprising up to 9 halogen atoms which can be the same or different; C₃-C₇-cycloalkyl; tri(C₁-C₈-alkyl)silyl or C₁-C₈-halogenoalkylsulfanyl comprising up to 9 halogen atoms which can be the same or different.

Other more preferred compounds of formula (I) according to the invention are those wherein the substitutents R¹ and R⁵, which can be the same or different, represent a halogen atom; C₁-C₈-alkyl; C₁-C₈-halogenoalkyl comprising up to 9 halogen atoms which can be the same or different; C₃-C₇-cycloalkyl; tri(C₁-C₈-alkyl)silyl or C₁-C₈-halogenoalkylsulfanyl comprising up to 9 halogen atoms which can be the same or different.

The above mentioned preferences with regard to the substituents of the compounds of formula (I) according to the invention can be combined in various manners, either individually, partially or entirely. These combinations of preferred features thus provide sub-classes of compounds according to the invention. Examples of such sub-classes of preferred compounds according to the invention can combine:

-   -   preferred features of T with preferred features of one or more         X¹, X², Y, Z¹ to Z³, and/or R¹ to R⁵;     -   preferred features of X¹ with preferred features of one or more         T, X², Y, Z¹ to Z³, and/or R¹ to R⁵;     -   preferred features of X² with preferred features of one or more         T, X¹, Y, Z¹ to Z³, and/or R¹ to R⁵;     -   preferred features of Y with preferred features of one or more         T, X¹, X², Z¹ to Z³, and/or R¹ to R⁵;     -   preferred features of Z¹ with preferred features of one or more         T, X¹, X², Y, Z², Z³, and/or R¹ to R⁵;     -   preferred features of Z² with preferred features of one or more         T, X¹, X², Y, Z¹, Z³, and/or R¹ to R⁵;     -   preferred features of Z³ with preferred features of one or more         T, X¹, X², Y, Z¹, Z², and/or R¹ to R⁵;     -   preferred features of R¹ with preferred features of one or more         T, X¹, X², Y, Z¹ to Z³, and/or R² to R⁵;     -   preferred features of R² with preferred features of one or more         T, X¹, X², Y, Z¹ to Z³, R¹, and/or R³ to R⁵;     -   preferred features of R³ with preferred features of one or more         T, X¹, X², Y, Z¹, to Z³, R¹, R², R⁴, and/or R⁵;     -   preferred features of R⁴ with preferred features of one or more         T, X¹, X², Y, Z¹ to Z³, R¹ to R³, and/or R⁵;     -   preferred features of R⁵ with preferred features of one or more         T, X¹, X², Y, Z¹ to Z³, and/or R¹ to R⁴;

In these combinations of preferred features of the substituents of the compounds according to the invention, the said preferred features can also be selected among the more preferred features of each of T, X¹, X², Y, Z¹ to Z³, and R¹ to R⁵; so as to form most preferred subclasses of compounds according to the invention.

The present invention also relates to a process for the preparation of the compound of formula (I). Thus, according to a further aspect of the present invention there is provided a process P1 for the preparation of a compound of formula (I) as herein defined and wherein T represents O and that comprises reaction of a N-substituted amine derivative of formula (II) or one of its salts:

wherein Z¹, Z², Z³, Y, R¹, R², R³ and R⁴ are as herein-defined; with a carboxylic acid derivative of formula (III):

wherein X¹ and X² are as herein defined and L¹ represents a leaving group selected in the list consisting of a halogen atom, a hydroxyl group, —OR^(a), —OC(═O)R^(a), R^(a) being a substituted or non-substituted C₁-C₆-alkyl, a substituted or non-substituted C₁-C₆-haloalkyl, a benzyl, a 4-methoxybenzyl or a pentafluorophenyl group; in the presence of a catalyst and in the presence of a condensing agent in case L¹ represents a hydroxyl group, and in the presence of an acid binder in case L¹ represents a halogen atom.

N-substituted amine derivatives of formula (II) are known or can be prepared by known processes such as reductive amination of aldehydes or ketones (Bioorganics and Medicinal Chemistry Letters (2006), 16, 2014), or reduction of imines (Tetrahedron (2005), 61, 11689), or nucleophilic substitution of a halogen, mesylate or tosylate (Journal of Medicinal Chemistry (2002), 45, 3887).

Carboxylic acid derivatives of formula (III) can be prepared according to process P2.

In case L¹ represents a hydroxy group, the process according to the present invention is conducted in the presence of a condensing agent. Suitable condensing agents may be selected in the non limited list consisting of acid halide former, such as phosgene, phosphorous tribromide, phosphorous trichloride, phosphorous pentachloride, phosphorous trichloride oxide or thionyl chloride; anhydride former, such as ethyl chloroformate, methyl chloroformate, isopropyl chloroformate, isobutyl chloroformate or methanesulfonyl chloride; carbodiimides, such as N,N′-dicyclohexylcarbodiimide (DCC) or other customary condensing agents, such as phosphorous pentoxide, polyphosphoric acid, N,N′-carbonyl-diimidazole, 2-ethoxy-N-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ), triphenyl-phosphine/tetrachloromethane, 4-(4,6-dimethoxy[1.3.5]-triazin-2-yl)-4-methylmorpholinium chloride hydrate, bromotripyrrolidinophosphonium hexafluorophosphate or propanephosphonic anhydride (T3P).

The process according to the present invention is conducted in the presence of a catalyst. Suitable catalyst may be selected in the list consisting of 4-dimethyl-aminopyridine, 1-hydroxy-benzotriazole or dimethylformamide.

In case L¹ represents a halogen atom, the process according to the present invention is conducted in the presence of an acid binder. Suitable acid binders for carrying out process P1 according to the invention are in each case all inorganic and organic bases that are customary for such reactions. Preference is given to using alkaline earth metal, alkali metal hydride, alkali metal hydroxides or alkali metal alkoxides, such as sodium hydroxide, sodium hydride, calcium hydroxide, potassium hydroxide, potassium tert-butoxide or other ammonium hydroxide, alkali metal carbonates, such as cesium carbonate, sodium carbonate, potassium carbonate, potassium bicarbonate, sodium bicarbonate, alkali metal or alkaline earth metal acetates, such as sodium acetate, potassium acetate, calcium acetateand also tertiary amines, such as trimethylamine, triethylamine, diisopropylethylamine, tributylamine, N,N-dimethylaniline, pyridine, N-methylpiperidine, N,N-dimethylaminopyridine, diazabicyclooctane (DABCO), diazabicyclo-nonene (DBN) or diazabicycloundecene (DBU). It is also possible to work in the absence of an additional condensing agent or to employ an excess of the amine component, so that it simultaneously acts as acid binder agent.

According to a further aspect according to the invention, there is provided a process P2 for the preparation of carboxylic acid derivatives of formula (III) wherein T represents O and illustrated according to the following reaction scheme:

wherein X² is as herein-defined;

-   5-chloro-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carbaldehyde is     known from WO-2004/014138 (reference example 35).

Step 1 of process P2 is performed in the presence of an oxidant, and if appropriate in the presence of a solvent.

Steps 2 and 5 of process P2 are performed in the presence of acid halide, and if appropriate in the presence of a solvent.

Step 3 of process P2 is performed in the presence of a fluorinating agent, and if appropriate in the presence of a solvent.

Step 4 of process P2 is performed in the presence of an acid or a base and if appropriate in the presence of a solvent

Suitable oxidants for carrying out step 1 of process P2 according to the invention are in each case all inorganic and organic oxidant which are customary for such reactions. Preference is given to using benzyltriethylammonium permanganate, bromine, chlorine, m-chloroperbenzoic acid, chromic acid, chromium (VI) oxide, hydrogen peroxide, hydrogen peroxide-boron trifluoride, hydrogen peroxide-urea, 2-hydroxyperoxyhexafluoro-2-propanol; Iodine, oxygen-platinum catalyst, perbenzoic acid, peroxyacetyl nitrate, potassium permanganate, potassium ruthenate, pyridinium dichromate, ruthenium (VIII) oxide, silver (I) oxide, silver (II) oxide, silver nitrite, sodium chlorite, sodium hypochlorite, or 2,2,6,6-tetramethylpiperidin-1-oxyl.

Suitable acid halides for carrying out steps 2 and 5 of process P2 according to the invention are in each case all organic or inorganic acid halides which are customary for such reactions. Preference is given to using notably phosgene, phosphorous trichloride, phosphorous pentachloride, phosphorous trichloride oxide, thionyl chloride, or carbon tetrachloride-triphenylphosphine.

Suitable fluorinating agents for carrying out step 3 of process P2 according to the invention is in each case all fluorinating agents which are customary for such reactions. Preference is given to using caesium fluoride, potassium fluoride, potassium fluoride-calcium difluoride, or tetrabutylammonium fluoride.

When carrying out steps 1 to 5 of process P2 according to the invention, the reaction temperatures can independently be varied within a relatively wide range. Generally, processes according to the invention are carried out at temperatures between 0° C. and 160° C., preferably between 10° C. and 120° C. A way to control the temperature for the processes according to the invention is to use the micro-wave technology.

Steps 1 to 5 of process P2 according to the invention are generally independently carried out under atmospheric pressure. However, in each case, it is also possible to operate under elevated or reduced pressure.

When carrying out step 1 of process P2 according to the invention, generally one mole or excess amount of the oxidant is employed per mole of aldehyde of formula (IV). It is also possible to employ the reaction components in other ratios.

When carrying out steps 2 and 5 of process P2 according to the invention, generally one mole or excess amount of the acid halides is employed per mole of acid of formula (IIIa) or (IIId). It is also possible to employ the reaction components in other ratios.

When carrying out steps 3 of process P2 according to the invention, generally one mole or excess amount of fluorinating agent is employed per mole of acid chloride (IIIb). It is also possible to employ the reaction components in other ratios.

When carrying out steps 4 of process P2 according to the invention, generally one mole or excess amount of acid or base is employed per mole of acid fluoride (IIIc). It is also possible to employ the reaction components in other ratios.

According to a further aspect of the invention, there is provided a process P3 for the preparation of a compound of formula (I) wherein T represents S, starting from a compound of formula (I) wherein T represents 0 and illustrated according to the following reaction scheme:

wherein X¹, X², Z¹, Z², Z³, Y, R¹, R², R³ and R⁴ are as herein defined, in the optional presence of a catalytic or stoichiometric or excess amount, quantity of a base such as an inorganic and organic base. Preference is given to using alkali metal carbonates, such as sodium carbonate, potassium carbonate, potassium bicarbonate, sodium bicarbonate; heterocyclic aromatic bases, such as pyridine, picoline, lutidine, collidine; and also tertiary amines, such as trimethylamine, triethylamine, tributylamine, N,N-dimethylaniline, N,N-dimethylaminopyridine or N-methyl-piperidine.

Process P3 according to the invention is performed in the presence of a thionating agent.

Starting amide derivatives of formula (I) can be prepared according to process P1.

Suitable thionating agents for carrying out process P3 according to the invention can be sulfur (S), sulfhydric acid (H2S), sodium sulfide (Na2S), sodium hydrosulfide (NaHS), boron trisulfide (B2S3), bis(diethylaluminium) sulfide ((AlEt2)2S), ammonium sulfide ((NH4)2S), phosphorous pentasulfide (P2S5), Lawesson's reagent (2,4-bis(4-methoxyphenyl)-1,2,3,4-dithiadiphos-phetane 2,4-disulfide) or a polymer-supported thionating reagent such as described in Journal of the Chemical Society, Perkin 1 (2001), 358.

Work-up is carried out by customary methods. Generally, the reaction mixture is treated with water and the organic phase is separated off and, after drying, concentrated under reduced pressure. If appropriate, the remaining residue can, be freed by customary methods, such as chromatography, recrystallization or distillation, from any impurities that may still be present.

The compound according to the present invention can be prepared according to the general processes of preparation described above. It will nevertheless be understood that, on the basis of his general knowledge and of available publications, the skilled worker will be able to adapt this method according to the specifics of each of the compounds, which it is desired to synthesize.

In a further aspect, the present invention also relates to a fungicide composition comprising an effective and non-phytotoxic amount of an active compound of formula (I).

The expression “effective and non-phytotoxic amount” means an amount of composition according to the invention that is sufficient to control or destroy the fungi present or liable to appear on the cropsand that does not entail any appreciable symptom of phytotoxicity for the said crops. Such an amount can vary within a wide range depending on the fungus to be controlled, the type of crop, the climatic conditions and the compounds included in the fungicide composition according to the invention. This amount can be determined by systematic field trials that are within the capabilities of a person skilled in the art.

Thus, according to the invention, there is provided a fungicide composition comprising, as an active ingredient, an effective amount of a compound of formula (I) as herein defined and an agriculturally acceptable support, carrier or filler.

According to the invention, the term “support” denotes a natural or synthetic, organic or inorganic compound with that the active compound of formula (I) is combined or associated to make it easier to apply, notably to the parts of the plant. This support is thus generally inert and should be agriculturally acceptable. The support can be a solid or a liquid. Examples of suitable supports include clays, natural or synthetic silicates, silica, resins, waxes, solid fertilisers, water, alcohols, in particular butanol, organic solvents, mineral and plant oils and derivatives thereof. Mixtures of such supports can also be used.

The composition according to the invention can also comprise additional components. In particular, the composition can further comprise a surfactant. The surfactant can be an emulsifier, a dispersing agent or a wetting agent of ionic or non-ionic type or a mixture of such surfactants. Mention can be made, for example, of polyacrylic acid salts, lignosulfonic acid salts, phenolsulfonic or naphthalenesulfonic acid salts, polycondensates of ethylene oxide with fatty alcohols or with fatty acids or with fatty amines, substituted phenols (in particular alkylphenols or arylphenols), salts of sulfosuccinic acid esters, taurine derivatives (in particular alkyl taurates), phosphoric esters of polyoxyethylated alcohols or phenols, fatty acid esters of polyolsand derivatives of the above compounds containing sulfate, sulfonate and phosphate functions. The presence of at least one surfactant is generally essential when the active compound and/or the inert support are water-insoluble and when the vector agent for the application is water. Preferably, surfactant content can be comprised from 5% to 40% by weight of the composition.

Optionally, additional components can also be included, e.g. protective colloids, adhesives, thickeners, thixotropic agents, penetration agents, stabilisers, sequestering agents. More generally, the active compounds can be combined with any solid or liquid additive, that complies with the usual formulation techniques.

In general, the composition according to the invention can contain from 0.05 to 99% by weight of active compound, preferably 10 to 70% by weight.

Compositions according to the invention can be used in various forms such as aerosol dispenser, capsule suspension, cold fogging concentrate, dustable powder, emulsifiable concentrate, emulsion oil in water, emulsion water in oil, encapsulated granule, fine granule, flowable concentrate for seed treatment, gas (under pressure), gas generating product, granule, hot fogging concentrate, macrogranule, microgranule, oil dispersible powder, oil miscible flowable concentrate, oil miscible liquid, paste, plant rodlet, powder for dry seed treatment, seed coated with a pesticide, soluble concentrate, soluble powder, solution for seed treatment, suspension concentrate (flowable concentrate), ultra low volume (ULV) liquid, ultra low volume (ULV) suspension, water dispersible granules or tablets, water dispersible powder for slurry treatment, water soluble granules or tablets, water soluble powder for seed treatment and wettable powder. These compositions include not only compositions that are ready to be applied to the plant or seed to be treated by means of a suitable device, such as a spraying or dusting device, but also concentrated commercial compositions that must be diluted before application to the crop.

The compounds according to the invention can also be mixed with one or more insecticide, fungicide, bactericide, attractant, acaricide or pheromone active substance or other compounds with biological activity. The mixtures thus obtained have normally a broadened spectrum of activity. The mixtures with other fungicide compounds are particularly advantageous.

Examples of suitable fungicide mixing partners can be selected in the following lists:

(1) Inhibitors of the ergosterol biosynthesis, for example (1.1) aldimorph (1704-28-5), (1.2) azaconazole (60207-31-0), (1.3) bitertanol (55179-31-2), (1.4) bromuconazole (116255-48-2), (1.5) cyproconazole (113096-99-4), (1.6) diclobutrazole (75736-33-3), (1.7) difenoconazole (119446-68-3), (1.8) diniconazole (83657-24-3), (1.9) diniconazole-M (83657-18-5), (1.10) dodemorph (1593-77-7), (1.11) dodemorph acetate (31717-87-0), (1.12) epoxiconazole (106325-08-0), (1.13) etaconazole (60207-93-4), (1.14) fenarimol (60168-88-9), (1.15) fenbuconazole (114369-43-6), (1.16) fenhexamid (126833-17-8), (1.17) fenpropidin (67306-00-7), (1.18) fenpropimorph (67306-03-0), (1.19) fluquinconazole (136426-54-5), (1.20) flurprimidol (56425-91-3), (1.21) flusilazole (85509-19-9), (1.22) flutriafol (76674-21-0), (1.23) furconazole (112839-33-5), (1.24) furconazole-cis (112839-32-4), (1.25) hexaconazole (79983-71-4), (1.26) imazalil (60534-80-7), (1.27) imazalil sulfate (58594-72-2), (1.28) imibenconazole (86598-92-7), (1.29) ipconazole (125225-28-7), (1.30) metconazole (125116-23-6), (1.31) myclobutanil (88671-89-0), (1.32) naftifine (65472-88-0), (1.33) nuarimol (63284-71-9), (1.34) oxpoconazole (174212-12-5), (1.35) paclobutrazol (76738-62-0), (1.36) pefurazoate (101903-30-4), (1.37) penconazole (66246-88-6), (1.38) piperalin (3478-94-2), (1.39) prochloraz (67747-09-5), (1.40) propiconazole (60207-90-1), (1.41) prothioconazole (178928-70-6), (1.42) pyributicarb (88678-67-5), (1.43) pyrifenox (88283-41-4), (1.44) quinconazole (103970-75-8), (1.45) simeconazole (149508-90-7), (1.46) spiroxamine (118134-30-8), (1.47) tebuconazole (107534-96-3), (1.48) terbinafine (91161-71-6), (1.49) tetraconazole (112281-77-3), (1.50) triadimefon (43121-43-3), (1.51) triadimenol (89482-17-7), (1.52) tridemorph (81412-43-3), (1.53) triflumizole (68694-11-1), (1.54) triforine (26644-46-2), (1.55) triticonazole (131983-72-7), (1.56) uniconazole (83657-22-1), (1.57) uniconazole-p (83657-17-4), (1.58) viniconazole (77174-66-4), (1.59) voriconazole (137234-62-9), (1.60) 1-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)cycloheptanol (129586-32-9), (1.61) methyl 1-(2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)-1H-imidazole-5-carboxylate (110323-95-0), (1.62) N′-{5-(difluoromethyl)-2-methyl-4-[3-(trimethylsilyl)propox]phenyl}-N-ethyl-N-methylimidoformamide, (1.63) N-ethyl-N-methyl-N′-{2-methyl-5-(trifluoromethyl)-4-[3-(trimethylsilyl)propoxy]phenyl}imidoformamide and (1.64) O-[1-(4-methoxyphenoxy)-3,3-dimethylbutan-2-yl]1H-imidazole-1-carbothioate (111226-71-2).

(2) inhibitors of the respiratory chain at complex I or II, for example (2.1) bixafen (581809-46-3), (2.2) boscalid (188425-85-6), (2.3) carboxin (5234-68-4), (2.4) diflumetorim (130339-07-0), (2.5) fenfuram (24691-80-3), (2.6) fluopyram (658066-35-4), (2.7) flutolanil (66332-96-5), (2.8) fluxapyroxad (907204-31-3), (2.9) furametpyr (123572-88-3), (2.10) furmecyclox (60568-05-0), (2.11) isopyrazam (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR,9SR) (881685-58-1), (2.12) isopyrazam (anti-epimeric racemate 1 RS,4SR,9SR), (2.13) isopyrazam (anti-epimeric enantiomer 1R,4S,9S), (2.14) isopyrazam (anti-epimeric enantiomer 1S,4R,9R), (2.15) isopyrazam (syn epimeric racemate 1RS,4SR,9RS), (2.16) isopyrazam (syn-epimeric enantiomer 1R,4S,9R), (2.17) isopyrazam (syn-epimeric enantiomer 1S,4R,9S), (2.18) mepronil (55814-41-0), (2.19) oxycarboxin (5259-88-1), (2.20) penflufen (494793-67-8), (2.21) penthiopyrad (183675-82-3), (2.22) sedaxane (874967-67-6), (2.23) thifluzamide (130000-40-7), (2.24) 1-methyl-N-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide, (2.25) 3-(difluoromethyl)-1-methyl-N-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-1H-pyrazole-4-carboxamide, (2.26) 3-(difluoromethyl)-N-[4-fluoro-2-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]-1-methyl-1H-pyrazole-4-carboxamide, (2.27) N-[1-(2,4-dichlorophenyl)-1-methoxypropan-2-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide (1092400-95-7) (WO 2008148570), (2.28) 5,8-difluoro-N-[2-(2-fluoro-4-{[4-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)ethyl]quinazolin-4-amine (1210070-84-0) (WO2010025451), (2.29) N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.30) N-[(1S,4R)-9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide and (2.31) N-[(1R,4S)-9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide.

(3) inhibitors of the respiratory chain at complex III, for example (3.1) ametoctradin (865318-97-4), (3.2) amisulbrom (348635-87-0), (3.3) azoxystrobin (131860-33-8), (3.4) cyazofamid (120116-88-3), (3.5) coumethoxystrobin (850881-30-0), (3.6) coumoxystrobin (850881-70-8), (3.7) dimoxystrobin (141600-52-4), (3.8) enestroburin (238410-11-2) (WO 2004/058723), (3.9) famoxadone (131807-57-3) (WO 2004/058723), (3.10) fenamidone (161326-34-7) (WO 2004/058723), (3.11) fenoxystrobin (918162-02-4), (3.12) fluoxastrobin (361377-29-9) (WO 2004/058723), (3.13) kresoxim-methyl (143390-89-0) (WO 2004/058723), (3.14) metominostrobin (133408-50-1) (WO 2004/058723), (3.15) orysastrobin (189892-69-1) (WO 2004/058723), (3.16) picoxystrobin (117428-22-5) (WO 2004/058723), (3.17) pyraclostrobin (175013-18-0) (WO 2004/058723), (3.18) pyrametostrobin (915410-70-7) (WO 2004/058723), (3.19) pyraoxystrobin (862588-11-2) (WO 2004/058723), (3.20) pyribencarb (799247-52-2) (WO 2004/058723), (3.21) triclopyricarb (902760-40-1), (3.22) trifloxystrobin (141517-21-7) (WO 2004/058723), (3.23) (2E)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoropyrimidin-4-yl]oxy}phenyl)-2-(methoxyimino)-N-methylethanamide (WO 2004/058723), (3.24) (2E)-2-(methoxyimino)-N-methyl-2-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}amino)oxy]methyl}phenyl)ethanamide (WO 2004/058723), (3.25) (2E)-2-(methoxyimino)-N-methyl-2-{2-[(E)-({1-[3-(trifluoromethyl)phenyl]ethoxy}imino)methyl]phenyl}ethanamide (158169-73-4), (3.26) (2E)-2-{2-[({[(1E)-1-(3-{[(E)-1-fluoro-2-phenylethenyl]oxy}phenyl)ethylidene]amino}oxy)methyl]phenyl}-2-(methoxyimino)-N-methylethanamide (326896-28-0), (3.27) (2E)-2-{2-[({[(2E,3E)-4-(2,6-dichlorophenyl)but-3-en-2-ylidene]amino}oxy)methyl]phenyl}-2-(methoxyimino)-N-methylethanamide, (3.28) 2-chloro-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)pyridine-3-carboxamide (119899-14-8), (3.29) 5-methoxy-2-methyl-4-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}amino)oxy]methyl}phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one, (3.30) methyl (2E)-2-{2-[({cyclopropyl[(4-methoxyphenyl)imino]methyl}sulfanyl)methyl]phenyl}-3-methoxyprop-2-enoate (149601-03-6), (3.31) N-(3-ethyl-3,5,5-trimethylcyclohexyl)-3-(formylamino)-2-hydroxybenzamide (226551-21-9), (3.32) 2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide (173662-97-0) and (3.33) (2R)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide (394657-24-0).

(4) Inhibitors of the mitosis and cell division, for example (4.1) benomyl (17804-35-2), (4.2) carbendazim (10605-21-7), (4.3) chlorfenazole (3574-96-7), (4.4) diethofencarb (87130-20-9), (4.5) ethaboxam (162650-77-3), (4.6) fluopicolide (239110-15-7), (4.7) fuberidazole (3878-19-1), (4.8) pencycuron (66063-05-6), (4.9) thiabendazole (148-79-8), (4.10) thiophanate-methyl (23564-05-8), (4.11) thiophanate (23564-06-9), (4.12) zoxamide (156052-68-5), (4.13) 5-chloro-7-(4-methylpiperidin-1-yl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine (214706-53-3) and (4.14) 3-chloro-5-(6-chloropyridin-3-yl)-6-methyl-4-(2,4,6-trifluorophenyl)pyridazine (1002756-87-7).

(5) Compounds capable to have a multisite action, like for example (5.1) bordeaux mixture (8011-63-0), (5.2) captafol (2425-06-1), (5.3) captan (133-06-2) (WO 02/12172), (5.4) chlorothalonil (1897-45-6), (5.5) copper hydroxide (20427-59-2), (5.6) copper naphthenate (1338-02-9), (5.7) copper oxide (1317-39-1), (5.8) copper oxychloride (1332-40-7), (5.9) copper(2+) sulfate (7758-98-7), (5.10) dichlofluanid (1085-98-9), (5.11) dithianon (3347-22-6), (5.12) dodine (2439-10-3), (5.13) dodine free base, (5.14) ferbam (14484-64-1), (5.15) fluorofolpet (719-96-0), (5.16) folpet (133-07-3), (5.17) guazatine (108173-90-6), (5.18) guazatine acetate, (5.19) iminoctadine (13516-27-3), (5.20) iminoctadine albesilate (169202-06-6), (5.21) iminoctadine triacetate (57520-17-9), (5.22) mancopper (53988-93-5), (5.23) mancozeb (8018-01-7), (5.24) maneb (12427-38-2), (5.25) metiram (9006-42-2), (5.26) metiram zinc (9006-42-2), (5.27) oxine-copper (10380-28-6), (5.28) propamidine (104-32-5), (5.29) propineb (12071-83-9), (5.30) sulfur and sulfur preparations including calcium polysulfide (7704-34-9), (5.31) thiram (137-26-8), (5.32) tolylfluanid (731-27-1), (5.33) zineb (12122-67-7) and (5.34) ziram (137-30-4).

(6) Compounds capable to induce a host defence, for example (6.1) acibenzolar-5-methyl (135158-54-2), (6.2) isotianil (224049-04-1), (6.3) probenazole (27605-76-1) and (6.4) tiadinil (223580-51-6).

(7) Inhibitors of the amino acid and/or protein biosynthesis, for example (7.1) andoprim (23951-85-1), (7.2) blasticidin-S (2079-00-7), (7.3) cyprodinil (121552-61-2), (7.4) kasugamycin (6980-18-3), (7.5) kasugamycin hydrochloride hydrate (19408-46-9), (7.6) mepanipyrim (110235-47-7), (7.7) pyrimethanil (53112-28-0) and (7.8) 3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinolin-1-yl)quinoline (861647-32-7) (WO2005070917).

(8) Inhibitors of the ATP production, for example (8.1) fentin acetate (900-95-8), (8.2) fentin chloride (639-58-7), (8.3) fentin hydroxide (76-87-9) and (8.4) silthiofam (175217-20-6).

(9) Inhibitors of the cell wall synthesis, for example (9.1) benthiavalicarb (177406-68-7), (9.2) dimethomorph (110488-70-5), (9.3) flumorph (211867-47-9), (9.4) iprovalicarb (140923-17-7), (9.5) mandipropamid (374726-62-2), (9.6) polyoxins (11113-80-7), (9.7) polyoxorim (22976-86-9), (9.8) validamycin A (37248-47-8) and (9.9) valifenalate (283159-94-4; 283159-90-0).

(10) Inhibitors of the lipid and membrane synthesis, for example (10.1) biphenyl (92-52-4), (10.2) chloroneb (2675-77-6), (10.3) dicloran (99-30-9), (10.4) edifenphos (17109-49-8), (10.5) etridiazole (2593-15-9), (10.6) iodocarb (55406-53-6), (10.7) iprobenfos (26087-47-8), (10.8) isoprothiolane (50512-35-1), (10.9) propamocarb (25606-41-1), (10.10) propamocarb hydrochloride (25606-41-1), (10.11) prothiocarb (19622-08-3), (10.12) pyrazophos (13457-18-6), (10.13) quintozene (82-68-8), (10.14) tecnazene (117-18-0) and (10.15) tolclofos-methyl (57018-04-9).

(11) Inhibitors of the melanine biosynthesis, for example (11.1) carpropamid (104030-54-8), (11.2) diclocymet (139920-32-4), (11.3) fenoxanil (115852-48-7), (11.4) phthalide (27355-22-2), (11.5) pyroquilon (57369-32-1), (11.6) tricyclazole (41814-78-2) and (11.7) 2,2,2-trifluoroethyl {3-methyl-1-[(4-methylbenzoyl)amino]butan-2-yl}carbamate (851524-22-6) (WO2005042474).

(12) Inhibitors of the nucleic acid synthesis, for example (12.1) benalaxyl (71626-11-4), (12.2) benalaxyl-M (kiralaxyl) (98243-83-5), (12.3) bupirimate (41483-43-6), (12.4) clozylacon (67932-85-8), (12.5) dimethirimol (5221-53-4), (12.6) ethirimol (23947-60-6), (12.7) furalaxyl (57646-30-7), (12.8) hymexazol (10004-44-1), (12.9) metalaxyl (57837-19-1), (12.10) metalaxyl-M (mefenoxam) (70630-17-0), (12.11) ofurace (58810-48-3), (12.12) oxadixyl (77732-09-3) and (12.13) oxolinic acid (14698-29-4).

(13) Inhibitors of the signal transduction, for example (13.1) chlozolinate (84332-86-5), (13.2) fenpiclonil (74738-17-3), (13.3) fludioxonil (131341-86-1), (13.4) iprodione (36734-19-7), (13.5) procymidone (32809-16-8), (13.6) quinoxyfen (124495-18-7) and (13.7) vinclozolin (50471-44-8).

(14) Compounds capable to act as an uncoupler, for example (14.1) binapacryl (485-31-4), (14.2) dinocap (131-72-6), (14.3) ferimzone (89269-64-7), (14.4) fluazinam (79622-59-6) and (14.5) meptyldinocap (131-72-6).

(15) Further compounds, for example (15.1) benthiazole (21564-17-0), (15.2) bethoxazin (163269-30-5), (15.3) capsimycin (70694-08-5), (15.4) carvone (99-49-0), (15.5) chinomethionat (2439-01-2), (15.6) pyriofenone (chlazafenone) (688046-61-9), (15.7) cufraneb (11096-18-7), (15.8) cyflufenamid (180409-60-3), (15.9) cymoxanil (57966-95-7), (15.10) cyprosulfamide (221667-31-8), (15.11) dazomet (533-74-4), (15.12) debacarb (62732-91-6), (15.13) dichlorophen (97-23-4), (15.14) diclomezine (62865-36-5), (15.15) difenzoquat (49866-87-7), (15.16) difenzoquat methylsulfate (43222-48-6), (15.17) diphenylamine (122-39-4), (15.18) ecomate, (15.19) fenpyrazamine (473798-59-3), (15.20) flumetover (154025-04-4), (15.21) fluoroimide (41205-21-4), (15.22) flusulfamide (106917-52-6), (15.23) flutianil (304900-25-2), (15.24) fosetyl-aluminium (39148-24-8), (15.25) fosetyl-calcium, (15.26) fosetyl-sodium (39148-16-8), (15.27) hexachlorobenzene (118-74-1), (15.28) irumamycin (81604-73-1), (15.29) methasulfocarb (66952-49-6), (15.30) methyl isothiocyanate (556-61-6), (15.31) metrafenone (220899-03-6), (15.32) mildiomycin (67527-71-3), (15.33) natamycin (7681-93-8), (15.34) nickel dimethyldithiocarbamate (15521-65-0), (15.35) nitrothal-isopropyl (10552-74-6), (15.36) octhilinone (26530-20-1), (15.37) oxamocarb (917242-12-7), (15.38) oxyfenthiin (34407-87-9), (15.39) pentachlorophenol and salts (87-86-5), (15.40) phenothrin, (15.41) phosphorous acid and its salts (13598-36-2), (15.42) propamocarb-fosetylate, (15.43) propanosine-sodium (88498-02-6), (15.44) proquinazid (189278-12-4), (15.45) pyrimorph (868390-90-3), (15.45e) (2E)-3-(4-tert-butylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one (1231776-28-5), (15.45z) (2Z)-3-(4-tert-butylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one (1231776-29-6), (15.46) pyrroInitrine (1018-71-9) (EP-A 1 559 320), (15.47) tebufloquin (376645-78-2), (15.48) tecloftalam (76280-91-6), (15.49) tolnifanide (304911-98-6), (15.50) triazoxide (72459-58-6), (15.51) trichlamide (70193-21-4), (15.52) zarilamid (84527-51-5), (15.53) (3S,6S,7R,8R)-8-benzyl-3-[({3-[(isobutyryloxy)methoxy]-4-methoxypyridin-2-yl}carbonyl)amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl 2-methylpropanoate (517875-34-2) (WO2003035617), (15.54) 1-(4-{4-[(5R)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (1003319-79-6) (WO 2008013622), (15.55) 1-(4-{4-[(5S)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (1003319-80-9) (WO 2008013622), (15.56) 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (1003318-67-9) (WO 2008013622), (15.57) 1-(4-methoxyphenoxy)-3,3-dimethylbutan-2-yl1H-imidazole-1-carboxylate (111227-17-9), (15.58) 2,3,5,6-tetrachloro-4-(methylsulfonyl)pyridine (13108-52-6), (15.59) 2,3-dibutyl-6-chlorothieno[2,3-d]pyrimidin-4(3H)-one (221451-58-7), (15.60) 2,6-dimethyl-1H,5H-[1,4]dithiino[2,3-c:5,6-c′]dipyrrole-1,3,5,7(2H,6H)-tetrone, (15.61) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5R)-5-phenyl-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone (1003316-53-7) (WO 2008013622), (15.62) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5S)-5-phenyl-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone (1003316-54-8) (WO 2008013622), (15.63) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-{4-[4-(5-phenyl-4,5-dihydro-1,2-oxazol-3-yl)-1,3-thiazol-2-yl]piperidin-1-yl}ethanone (1003316-51-5) (WO 2008013622), (15.64) 2-butoxy-6-iodo-3-propyl-4H-chromen-4-one, (15.65) 2-chloro-5-[2-chloro-1-(2,6-difluoro-4-methoxyphenyl)-4-methyl-1H-imidazol-5-yl]pyridine, (15.66) 2-phenylphenol and salts (90-43-7), (15.67) 3-(4,4,5-trifluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline (861647-85-0) (WO2005070917), (15.68) 3,4,5-trichloropyridine-2,6-dicarbonitrile (17824-85-0), (15.69) 3-[5-(4-chlorophenyl)-2,3-dimethyl-1,2-oxazolidin-3-yl]pyridine, (15.70) 3-chloro-5-(4-chlorophenyl)-4-(2,6-difluorophenyl)-6-methylpyridazine, (15.71) 4-(4-chlorophenyl)-5-(2,6-difluorophenyl)-3,6-dimethylpyridazine, (15.72) 5-amino-1,3,4-thiadiazole-2-thiol, (15.73) 5-chloro-N′-phenyl-N′-(prop-2-yn-1-yl)thiophene-2-sulfonohydrazide (134-31-6), (15.74) 5-fluoro-2-[(4-fluorobenzyl)oxy]pyrimidin-4-amine (1174376-11-4) (WO2009094442), (15.75) 5-fluoro-2-[(4-methylbenzyl)oxy]pyrimidin-4-amine (1174376-25-0) (WO2009094442), (15.76) 5-methyl-6-octyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine, (15.77) ethyl (2Z)-3-amino-2-cyano-3-phenylprop-2-enoate, (15.78) N′-(4-{[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]oxy}-2,5-dimethylphenyl)-N-ethyl-N-methylimidoformamide, (15.79) N-(4-chlorobenzyl)-3-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]propanamide, (15.80) N-[(4-chlorophenyl)(cyano)methyl]-3-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]propanamide, (15.81) N-[(5-bromo-3-chloropyridin-2-yl)methyl]-2,4-dichloropyridine-3-carboxamide, (15.82) N-[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2,4-dichloropyridine-3-carboxamide, (15.83) N-[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2-fluoro-4-iodopyridine-3-carboxamide, (15.84) N-{(E)-[(cyclopropylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl]methyl}-2-phenylacetamide (221201-92-9), (15.85) N-{(Z)-[(cyclopropylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl]methyl}-2-phenylacetamide (221201-92-9), (15.86) N′-{4-[(3-tert-butyl-4-cyano-1,2-thiazol-5-yl)oxy]-2-chloro-5-methylphenyl}-N-ethyl-N-methylimidoformamide, (15.87) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3-thiazole-4-carboxamide (922514-49-6) (WO 2007014290), (15.88) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazole-4-carboxamide (922514-07-6) (WO 2007014290), (15.89) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazole-4-carboxamide (922514-48-5) (WO 2007014290), (15.90) pentyl {6-[({[(1-methyl-1H-tetrazol-5-yl)(phenyl)methylidene]amino}oxy)methyl]pyridin-2-yl}carbamate, (15.91) phenazine-1-carboxylic acid, (15.92) quinolin-8-ol (134-31-6), (15.93) quinolin-8-ol sulfate (2:1) (134-31-6) and (15.94) tert-butyl {6[({[(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl}carbamate.

(16) Further compounds, for example (16.1) 1-methyl-3-(trifluoromethyl)-N-[2′-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide, (16.2) N-(4′-chlorobiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (16.3) N-(2′,4′-dichlorobiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (16.4) 3-(difluoromethyl)-1-methyl-N-[4′-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide, (16.5) N-(2′,5′-difluorobiphenyl-2-yl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide, (16.6) 3-(difluoromethyl)-1-methyl-N-[4′-(prop-1-yn-1-yl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (16.7) 5-fluoro-1,3-dimethyl-N-[4′-(prop-1-yn-1-yl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (16.8) 2-chloro-N-[4′-(prop-1-yn-1-yl)biphenyl-2-yl]pyridine-3-carboxamide (known from WO 2004/058723), (16.9) 3-(difluoromethyl)-N-[4′-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]-1-methyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (16.10) N-[4′-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (16.11) 3-(difluoromethyl)-N-(4′-ethynylbiphenyl-2-yl)-1-methyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (16.12) N-(4′-ethynylbiphenyl-2-yl)-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (16.13) 2-chloro-N-(4′-ethynylbiphenyl-2-yl)pyridine-3-carboxamide (known from WO 2004/058723), (16.14) 2-chloro-N-[4′-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]pyridine-3-carboxamide (known from WO 2004/058723), (16.15) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-5-carboxamide (known from WO 2004/058723), (16.16) 5-fluoro-N-[4′-(3-hydroxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (16.17) 2-chloro-N-[4′-(3-hydroxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]pyridine-3-carboxamide (known from WO 2004/058723), (16.18) 3-(difluoromethyl)-N-[4′-(3-methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]-1-methyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (16.19) 5-fluoro-N-[4′-(3-methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (16.20) 2-chloro-N-[4′-(3-methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]pyridine-3-carboxamide (known from WO 2004/058723), (16.21) (5-bromo-2-methoxy-4-methylpyridin-3-yl)(2,3,4-trimethoxy-6-methylphenyl)methanone (known from EP-A 1 559 320), (16.22) N-[2-(4-{[3-(4-chlorophenyl)prop-2-yn-1-yl]oxy}-3-methoxyphenyl)ethyl]-N2-(methylsulfonyl)valinamide (220706-93-4), (16.23) 4-oxo-4-[(2-phenylethyl)amino]butanoic acid and (16.24) but-3-yn-1-yl{6-[({[(Z)-(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl}carbamate.

All named mixing partners of the classes (1) to (16) can, if their functional groups enable this, optionally form salts with suitable bases or acids.

Examples of suitable bactericides, insecticides, acaricides or nematicides mixing partners can be selected in the following lists:

Bactericides:

Bronopol, dichlorophen, nitrapyrin, nickel dimethyl dithiocarbamate, kasugamycin, octhilinone, furan-carboxylic acid, oxytetracyclin, probenazole, streptomycin, tecloftalam, copper sulfate and other copper preparations.

Insecticides/Acaricides/Nematicides:

(1) Acetylcholinesterase (AChE) inhibitors, for example

carbamates, e.g. Alanycarb, Aldicarb, Bendiocarb, Benfuracarb, Butocarboxim, Butoxycarboxim, Carbaryl, Carbofuran, Carbosulfan, Ethiofencarb, Fenobucarb, Formetanate, Furathiocarb, Isoprocarb, Methiocarb, Methomyl, Metolcarb, Oxamyl, Pirimicarb, Propoxur, Thiodicarb, Thiofanox, Triazamate, Trimethacarb, XMC, and Xylylcarb; or

organophosphates, e.g. Acephate, Azamethiphos, Azinphos-ethyl, Azinphos-methyl, Cadusafos, Chlorethoxyfos, Chlorfenvinphos, Chlormephos, Chlorpyrifos, Chlorpyrifos-methyl, Coumaphos, Cyanophos, Demeton-5-methyl, Diazinon, Dichlorvos/DDVP, Dicrotophos, Dimethoate, Dimethylvinphos, Disulfoton, EPN, Ethion, Ethoprophos, Famphur, Fenamiphos, Fenitrothion, Fenthion, Fosthiazate, Heptenophos, Imicyafos, Isofenphos, Isopropyl O-(methoxyaminothio-phosphoryl) salicylate, Isoxathion, Malathion, Mecarbam, Methamidophos, Methidathion, Mevinphos, Monocrotophos, Naled, Omethoate, Oxydemeton-methyl, Parathion, Parathion-methyl, Phenthoate, Phorate, Phosalone, Phosmet, Phosphamidon, Phoxim, Pirimiphos-methyl, Profenofos, Propetamphos, Prothiofos, Pyraclofos, Pyridaphenthion, Quinalphos, Sulfotep, Tebupirimfos, Temephos, Terbufos, Tetrachlorvinphos, Thiometon, Triazophos, Trichlorfon, and Vamidothion.

(2) GABA-gated chloride channel antagonists, for example

cyclodiene organochlorines, e.g. Chlordane and Endosulfan; or

phenylpyrazoles (fiproles), e.g. Ethiprole and Fipronil.

(3) Sodium channel modulators/voltage-dependent sodium channel blockers, for example

pyrethroids, e.g. Acrinathrin, Allethrin, d-cis-trans Allethrin, d-trans Allethrin, Bifenthrin, Bioallethrin, Bioallethrin 5-cyclopentenyl isomer, Bioresmethrin, Cycloprothrin, Cyfluthrin, beta-Cyfluthrin, Cyhalothrin, lambda-Cyhalothrin, gamma-Cyhalothrin, Cypermethrin, alpha-Cypermethrin, beta-Cypermethrin, theta-Cypermethrin, zeta-Cypermethrin, Cyphenothrin [(1R)-trans isomers], Deltamethrin, Empenthrin [(EZ)-(1R) isomers), Esfenvalerate, Etofenprox, Fenpropathrin, Fenvalerate, Flucythrinate, Flumethrin, tau-Fluvalinate, Halfenprox, Imiprothrin, Kadethrin, Permethrin, Phenothrin [(1R)-trans isomer), Prallethrin, Pyrethrine (pyrethrum), Resmethrin, Silafluofen, Tefluthrin, Tetramethrin, Tetramethrin [(1R) isomers)], Tralomethrin, and Transfluthrin; or

DDT; or Methoxychlor.

(4) Nicotinic acetylcholine receptor (nAChR) agonists, for example

neonicotinoids, e.g. Acetamiprid, Clothianidin, Dinotefuran, Imidacloprid, Nitenpyram, Thiacloprid, and Thiamethoxam; or

Nicotine.

(5) Nicotinic acetylcholine receptor (nAChR) allosteric activators, for example

spinosyns, e.g. Spinetoram and Spinosad.

(6) Chloride channel activators, for example

avermectins/milbemycins, e.g. Abamectin, Emamectin benzoate, Lepimectin, and Milbemectin.

(7) Juvenile hormone mimics, for example

juvenile hormon analogues, e.g. Hydroprene, Kinoprene, and Methoprene; or

Fenoxycarb; or Pyriproxyfen.

(8) Miscellaneous non-specific (multi-site) inhibitors, for example

alkyl halides, e.g. Methyl bromide and other alkyl halides; or

Chloropicrin; or Sulfuryl fluoride; or Borax; or Tartar emetic.

(9) Selective homopteran feeding blockers, e.g. Pymetrozine; or Flonicamid.

(10) Mite growth inhibitors, e.g. Clofentezine, Hexythiazox, and Diflovidazin; or

Etoxazole.

(11) Microbial disruptors of insect midgut membranes, e.g. Bacillus thuringiensis subspecies israelensis, Bacillus sphaericus, Bacillus thuringiensis subspecies aizawai, Bacillus thuringiensis subspecies kurstaki, Bacillus thuringiensis subspecies tenebrionis, and BT crop proteins: Cry1Ab, Cry1Ac, Cry1Fa, Cry2Ab, mCry3A, Cry3Ab, Cry3Bb, Cry34/35Ab1.

(12) Inhibitors of mitochondria! ATP synthase, for example Diafenthiuron; or

organotin miticides, e.g. Azocyclotin, Cyhexatin, and Fenbutatin oxide; or

Propargite; or Tetradifon.

(13) Uncouplers of oxidative phoshorylation via disruption of the proton gradient, for example Chlorfenapyr, DNOC, and Sulfluramid.

(14) Nicotinic acetylcholine receptor (nAChR) channel blockers, for example Bensultap, Cartap hydrochloride, Thiocyclam, and Thiosultap-sodium.

(15) Inhibitors of chitin biosynthesis, type 0, for example Bistrifluoron, Chlorfluazuron, Diflubenzuron, Flucycloxuron, Flufenoxuron, Hexaflumuron, Lufenuron, Novaluron, Noviflumuron, Teflubenzuron, and Triflumuron.

(16) Inhibitors of chitin biosynthesis, type 1, for example Buprofezin.

(17) Moulting disruptors, for example Cyromazine.

(18) Ecdysone receptor agonists, for example Chromafenozide, Halofenozide, Methoxyfenozide, and Tebufenozide.

(19) Octopamine receptor agonists, for example Amitraz.

(20) Mitochondrial complex III electron transport inhibitors, for example Hydramethylnon; or Acequinocyl; or Fluacrypyrim.

(21) Mitochondrial complex I electron transport inhibitors, for example

METI acaricides, e.g. Fenazaquin, Fenpyroximate, Pyrimidifen, Pyridaben, Tebufenpyrad, and Tolfenpyrad; or

Rotenone (Derris).

(22) Voltage-dependent sodium channel blockers, e.g. Indoxacarb; or Metaflumizone.

(23) Inhibitors of acetyl CoA carboxylase, for example tetronic and tetramic acid derivatives, e.g. Spirodiclofen, Spiromesifen, and Spirotetramat.

(24) Mitochondrial complex IV electron transport inhibitors, for example phosphines, e.g. Aluminium phosphide, Calcium phosphide, Phosphine, and Zinc phosphide; or Cyanide.

(25) Mitochondrial complex II electron transport inhibitors, for example Cyenopyrafen.

(28) Ryanodine receptor modulators, for example

diamides, e.g. Chlorantraniliprole and Flubendiamide.

Further active ingredients with unknown or uncertain mode of action, for example Amidoflumet, Azadirachtin, Benclothiaz, Benzoximate, Bifenazate, Bromopropylate, Chinomethionat, Cryolite, Cyantraniliprole (Cyazypyr), Cyflumetofen, Dicofol, Diflovidazin, Fluensulfone, Flufenerim, Flufiprole, Fluopyram, Fufenozide, Imidaclothiz, Iprodione, Meperfluthrin, Pyridalyl, Pyrifluquinazon, Tetramethylfluthrin, and iodomethane; furthermore products based on Bacillus firmus (including but not limited to strain CNCM 1-1582, such as, for example, VOTiVO™, BioNem) or one of the following known active compounds: 3-bromo-N-{2-bromo-4-chloro-6-[(1-cyclopropylethyl)carbamoyl]phenyl}-1-(3-chloropyridin-2-yl)-1H-pyrazole-5-carboxamide (known from WO2005/077934), 4-{[(6-bromopyridin-3-yl)methyl](2-fluoroethyl)amino}furan-2(5H)-one (known from WO2007/115644), 4-{[(6-fluoropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one (known from WO2007/115644), 4-{[(2-chloro-1,3-thiazol-5-yl)methyl](2-fluoroethyl)amino}furan-2(5H)-one (known from WO2007/115644), 4-{[(6-chlorpyridin-3-yl)methyl](2-fluoroethyl)amino}furan-2(5H)-one (known from WO2007/115644), Flupyradifurone, 4-{[(6-chlor-5-fluoropyridin-3-yl)methyl](methyl)amino}furan-2(5H)-one (known from WO2007/115643), 4-{[(5,6-dichloropyridin-3-yl)methyl](2-fluoroethyl)amino}furan-2(5H)-one (known from WO2007/115646), 4-{[(6-chloro-5-fluoropyridin-3-yl)methyl](cyclopropyl)amino}furan-2(5H)-one (known from WO2007/115643), 4-{[(6-chloropyridin-3-yl)methyl](cyclopropyl)amino}furan-2(5H)-one (known from EP-A-0 539 588), 4-{[(6-chlorpyridin-3-yl)methyl](methyl)amino}furan-2(5H)-one (known from EP-A-0 539 588), {[1-(6-chloropyridin-3-yl)ethyl](methyl)oxido-λ⁴-sulfanylidene}cyanamide (known from WO2007/149134) and its diastereomers {[(1R)-1-(6-chloropyridin-3-yl)ethyl]methyl)oxido-λ⁴-sulfanylidene}cyanamide (A) and {[(1S)-1-(6-chloropyridin-3-yl)ethyl]methyl)oxido-λ⁴-sulfanylidene}cyanamide (B) (also known from WO2007/149134) as well as Sulfoxaflor and its diastereomers [(R)-methyl(oxido){(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-λ⁴-sulfanylidene]cyanamide (A1) and [(S)-methyl(oxido){(1S)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-λ⁴-sulfanylidene]cyanamide (A2), referred to as group of diastereomers A (known from WO2010/074747, WO2010/074751), [(R)-methyl(oxido){(1S)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-λ⁴-sulfanylidene]cyanamide (B1) and [(S)-methyl(oxido){(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-λ⁴-sulfanylidene]cyanamide (B2), referred to as group of diastereomers B (also known from WO2010/074747, WO2010/074751), and 11-(4-chloro-2,6-dimethylphenyl)-12-hydroxy-1,4-dioxa-9-azadispiro[4.2.4.2]tetradec-11-en-10-one (known from WO2006/089633), 3-(4′-fluoro-2,4-dimethylbiphenyl-3-yl)-4-hydroxy-8-oxa-1-azaspiro[4.5]dec-3-en-2-one (known from WO2008/067911), 1-{2-fluoro-4-methyl-5-[(2,2,2-trifluorethyl)sulfinyl]phenyl}-3-(trifluoromethyl)-1H-1,2,4-triazol-5-amine (known from WO2006/043635), [(3S,4aR,12R,12aS,12bS)-3-[(cyclopropylcarbonyl)oxy]-6,12-dihydroxy-4,12b-dimethyl-11-oxo-9-(pyridin-3-yl)-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromen-4-yl]methyl cyclopropanecarboxylate (known from WO2008/066153), 2-cyano-3-(difluoromethoxy)-N,N-dimethylbenzenesulfonamide (known from WO2006/056433), 2-cyano-3-(difluoromethoxy)-N-methylbenzenesulfonamide (known from WO2006/100288), 2-cyano-3-(difluoromethoxy)-N-ethylbenzenesulfonamide (known from WO2005/035486), 4-(difluoromethoxy)-N-ethyl-N-methyl-1,2-benzothiazol-3-amine 1,1-dioxide (known from WO2007/057407), N-[1-(2,3-dimethylphenyl)-2-(3,5-dimethylphenyl)ethyl]-4,5-dihydro-1,3-thiazol-2-amine (known from WO2008/104503), {1′-[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl]-5-fluorospiro[indole-3,4′-piperidin]-1(2H)-yl}(2-chloropyridin-4-yl)methanone (known from WO2003/106457), 3-(2,5-dimethylphenyl)-4-hydroxy-8-methoxy-1,8-diazaspiro[4.5]dec-3-en-2-one (known from WO2009/049851), 3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1,8-diazaspiro[4.5]dec-3-en-4-yl ethyl carbonate (known from WO2009/049851), 4-(but-2-yn-1-yloxy)-6-(3,5-dimethylpiperidin-1-yl)-5-fluoropyrimidine (known from WO2004/099160), (2,2,3,3,4,4,5,5-octafluoropentyl)(3,3,3-trifluoropropyl)malononitrile (known from WO2005/063094), (2,2,3,3,4,4,5,5-octafluoropentyl)(3,3,4,4,4-pentafluorobutyl)malononitrile (known from WO2005/063094), 8-[2-(cyclopropylmethoxy)-4-(trifluoromethyl)phenoxy]-3-[6-(trifluoromethyl)pyridazin-3-yl]-3-azabicyclo[3.2.1]octane (known from WO2007/040280), Flometoquin, PF1364 (CAS-Reg. No. 1204776-60-2) (known from JP2010/018586), 5-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-(1H-1,2,4-triazol-1-yl)benzonitrile (known from WO2007/075459), 5-[5-(2-chloropyridin-4-yl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-(1H-1,2,4-triazol-1-yl)benzonitrile (known from WO2007/075459), 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methyl-N-{2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl}benzamide (known from WO2005/085216), 4-{[(6-chloropyridin-3-yl)methyl](cyclopropyl)amino}-1,3-oxazol-2(5H)-one, 4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}-1,3-oxazol-2(5H)-one, 4-{[(6-chloropyridin-3-yl)methyl](ethyl)amino}-1,3-oxazol-2(5H)-one, 4-{[(6-chloropyridin-3-yl)methyl](methyl)amino}-1,3-oxazol-2(5H)-one (all known from WO2010/005692), NNI-0711 (known from WO2002/096882), 1-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-methoxypropan-2-yl)-3-isobutylphenyl]-N-isobutyryl-3,5-dimethyl-1H-pyrazole-4-carboxamide (known from WO2002/096882), methyl 2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-chloro-3-methylbenzoyl]-2-methylhydrazinecarboxylate (known from WO2005/085216), methyl 2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-cyano-3-methylbenzoyl]-2-ethylhydrazinecarboxylate (known from WO2005/085216), methyl 2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-cyano-3-methylbenzoyl]-2-methylhydrazinecarboxylate (known from WO2005/085216), methyl 2-[3,5-dibromo-2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)benzoyl]-1,2-diethylhydrazinecarboxylate (known from WO2005/085216), methyl 2-[3,5-dibromo-2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)benzoyl]-2-ethylhydrazinecarboxylate (known from WO2005/085216), (5RS,7RS;5RS,7SR)-1-(6-chloro-3-pyridylmethyl)-1,2,3,5,6,7-hexahydro-7-methyl-8-nitro-5-propoxyimidazo[1,2-a]pyridine (known from WO2007/101369), 2-{6-[2-(5-fluoropyridin-3-yl)-1,3-thiazol-5-yl]pyridin-2-yl}pyrimidine (known from WO2010/006713), 2-{6-[2-(pyridin-3-yl)-1,3-thiazol-5-yl]pyridin-2-yl}pyrimidine (known from WO2010/006713), 1-(3-chloropyridin-2-yl)-N-[4-cyano-2-methyl-6-(methylcarbamoyl)phenyl]-3-{[5-(trifluoromethyl)-1H-tetrazol-1-yl]methyl}-1H-pyrazole-5-carboxamide (known from WO2010/069502), 1-(3-chloropyridin-2-yl)-N-[4-cyano-2-methyl-6-(methylcarbamoyl)phenyl]-3-{[5-(trifluoromethyl)-2H-tetrazol-2-yl]methyl}-1H-pyrazole-5-carboxamide (known from WO2010/069502), N-[2-(tert-butylcarbamoyl)-4-cyano-6-methylphenyl]-1-(3-chloropyridin-2-yl)-3-{[5-(trifluoromethyl)-1H-tetrazol-1-yl]methyl}-1H-pyrazole-5-carboxamide (known from WO2010/069502), N-[2-(tert-butylcarbamoyl)-4-cyano-6-methylphenyl]-1-(3-chloropyridin-2-yl)-3-{[5-(trifluoromethyl)-2H-tetrazol-2-yl]methyl}-1H-pyrazole-5-carboxamide (known from WO2010/069502), (1E)-N-[(6-chloropyridin-3-yl)methyl]-N′-cyano-N-(2,2-difluoroethyl)ethanimidamide (known from WO2008/009360), N-[2-(5-amino-1,3,4-thiadiazol-2-yl)-4-chloro-6-methylphenyl]-3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazole-5-carboxamide (known from CN102057925), and methyl 2-[3,5-dibromo-2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)benzoyl]-2-ethyl-1-methylhydrazinecarboxylate (known from WO2011/049233).

A mixture with other known active compounds such as herbicides, or with fertilizers and growth regulators, safeners or semiochemicals is also possible.

In addition, the compounds of the formula (I) according to the invention also have very good antimycotic activity. They have a very broad antimycotic spectrum of action, in particular against dermatophytes and budding fungi, moulds and diphasic fungi (for example against Candida species such as Candida albicans, Candida glabrata) and Epidermophyton floccosum, Aspergillus species such as Aspergillus niger and Aspergillus fumigatus, Trichophyton species such as Trichophyton mentagrophytes, Microsporon species such as Microsporon canis and audouinii. The enumeration of these fungi is no restriction whatsoever of the mycotic spectrum which can be controlled and is provided by illustration only.

The compounds of formula (I) and the fungicide composition according to the invention can be used to curatively or preventively control the phytopathogenic fungi of plants or crops.

Thus, according to a further aspect of the invention, there is provided a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops characterised in that a compound of formula (I) or a fungicide composition according to the invention is applied to the seed, the plant or to the fruit of the plant or to the soil wherein the plant is growing or wherein it is desired to grow.

The method of treatment according to the invention can also be useful to treat propagation material such as tubers or rhizomes, but also seeds, seedlings or seedlings pricking out and plants or plants pricking out. This method of treatment can also be useful to treat roots. The method of treatment according to the invention can also be useful to treat the overground parts of the plant such as trunks, stems or stalks, leaves, flowers and fruit of the concerned plant.

According to the invention all plants and plant parts can be treated. By plants is meant all plants and plant populations such as desirable and undesirable wild plants, cultivars and plant varieties (whether or not protectable by plant variety or plant breeder's rights). Cultivars and plant varieties can be plants obtained by conventional propagation and breeding methods which can be assisted or supplemented by one or more biotechnological methods such as by use of double haploids, protoplast fusion, random and directed mutagenesis, molecular or genetic markers or by bioengineering and genetic engineering methods. By plant parts is meant all above ground and below ground parts and organs of plants such as shoot, leaf, blossom and root, whereby for example leaves, needles, stems, branches, blossoms, fruiting bodies, fruits and seed as well as roots, corms and rhizomes are listed. Crops and vegetative and generative propagating material, for example cuttings, corms, rhizomes, runners and seeds also belong to plant parts. Among the plants that can be protected by the method according to the invention, mention may be made of major field crops like corn, soybean, cotton, Brassica oilseeds such as Brassica napus (e.g. canola), Brassica rapa, B. juncea (e.g. mustard) and Brassica carinata, rice, wheat, sugarbeet, sugarcane, oats, rye, barley, millet, triticale, flax, vine and various fruits and vegetables of various botanical taxa such as Rosaceae sp. (for instance pip fruit such as apples and pears, but also stone fruit such as apricots, cherries, almonds and peaches, berry fruits such as strawberries), Ribesioidae sp., Juglandaceae sp., Betulaceae sp., Anacardiaceae sp., Fagaceae sp., Moraceae sp., Oleaceae sp., Actimidaceae sp., Lauraceae sp., Musaceae sp. (for instance banana trees and plantings), Rubiaceae sp. (for instance coffee), Theaceae sp., Sterculiceae sp., Rutaceae sp. (for instance lemons, oranges and grapefruit); Solanaceae sp. (for instance tomatoes, potatoes, peppers, eggplant), Liliaceae sp., Compositiae sp. (for instance lettuce, artichoke and chicory—including root chicory, endive or common chicory), Umbelliferae sp. (for instance carrot, parsley, celery and celeriac), Cucurbitaceae sp. (for instance cucumber—including pickling cucumber, squash, watermelon, gourds and melons), Alliaceae sp. (for instance onions and leek), Cruciferae sp. (for instance white cabbage, red cabbage, broccoli, cauliflower, brussel sprouts, pak choi, kohlrabi, radish, horseradish, cress, Chinese cabbage), Leguminosae sp. (for instance peanuts, peas and beans beans—such as climbing beans and broad beans), Chenopodiaceae sp. (for instance mangold, spinach beet, spinach, beetroots), Malvaceae (for instance okra), Asparagaceae (for instance asparagus); horticultural and forest crops; ornamental plants; as well as genetically modified homologues of these crops.

The method of treatment according to the invention can be used in the treatment of genetically modified organisms (GMOs), e.g. plants or seeds. Genetically modified plants (or transgenic plants) are plants of which a heterologous gene has been stably integrated into genome. The expression “heterologous gene” essentially means a gene which is provided or assembled outside the plant and when introduced in the nuclear, chloroplastic or mitochondrial genome gives the transformed plant new or improved agronomic or other properties by expressing a protein or polypeptide of interest or by downregulating or silencing other gene(s) which are present in the plant (using for example, antisense technology, cosuppression technology or RNA interference—RNAi—technology). A heterologous gene that is located in the genome is also called a transgene. A transgene that is defined by its particular location in the plant genome is called a transformation or transgenic event.

Depending on the plant species or plant cultivars, their location and growth conditions (soils, climate, vegetation period, diet), the treatment according to the invention may also result in superadditive (“synergistic”) effects. Thus, for example, reduced application rates and/or a widening of the activity spectrum and/or an increase in the activity of the active compounds and compositions which can be used according to the invention, better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to water or soil salt content, increased flowering performance, easier harvesting, accelerated maturation, higher harvest yields, bigger fruits, larger plant height, greener leaf color, earlier flowering, higher quality and/or a higher nutritional value of the harvested products, higher sugar concentration within the fruits, better storage stability and/or processability of the harvested products are possible, which exceed the effects which were actually to be expected.

At certain application rates, the active compound combinations according to the invention may also have a strengthening effect in plants. Accordingly, they are also suitable for mobilizing the defense system of the plant against attack by unwanted microorganisms. This may, if appropriate, be one of the reasons of the enhanced activity of the combinations according to the invention, for example against fungi. Plant-strengthening (resistance-inducing) substances are to be understood as meaning, in the present context, those substances or combinations of substances which are capable of stimulating the defense system of plants in such a way that, when subsequently inoculated with unwanted microorganisms, the treated plants display a substantial degree of resistance to these microorganisms. In the present case, unwanted microorganisms are to be understood as meaning phytopathogenic fungi, bacteria and viruses. Thus, the substances according to the invention can be employed for protecting plants against attack by the abovementioned pathogens within a certain period of time after the treatment. The period of time within which protection is effected generally extends from 1 to 10 days, preferably 1 to 7 days, after the treatment of the plants with the active compounds.

Plants and plant cultivars which are preferably to be treated according to the invention include all plants which have genetic material which impart particularly advantageous, useful traits to these plants (whether obtained by breeding and/or biotechnological means).

Plants and plant cultivars which are also preferably to be treated according to the invention are resistant against one or more biotic stresses, i.e. said plants show a better defense against animal and microbial pests, such as against nematodes, insects, mites, phytopathogenic fungi, bacteria, viruses and/or viroids.

Examples of nematode resistant plants are described in e.g. U.S. patent application Ser. Nos. 11/765,491, 11/765,494, 10/926,819, 10/782,020, 12/032,479, 10/783,417, 10/782,096, 11/657,964, 12/192,904, 11/396,808, 12/166,253, 12/166,239, 12/166,124, 12/166,209, 11/762,886, 12/364,335, 11/763,947, 12/252,453, 12/209,354, 12/491,396 or 12/497,221.

Plants and plant cultivars which may also be treated according to the invention are those plants which are resistant to one or more abiotic stresses. Abiotic stress conditions may include, for example, drought, cold temperature exposure, heat exposure, osmotic stress, flooding, increased soil salinity, increased mineral exposure, ozone exposure, high light exposure, limited availability of nitrogen nutrients, limited availability of phosphorus nutrients, shade avoidance.

Plants and plant cultivars which may also be treated according to the invention, are those plants characterized by enhanced yield characteristics. Increased yield in said plants can be the result of, for example, improved plant physiology, growth and development, such as water use efficiency, water retention efficiency, improved nitrogen use, enhanced carbon assimilation, improved photosynthesis, increased germination efficiency and accelerated maturation. Yield can furthermore be affected by improved plant architecture (under stress and non-stress conditions), including but not limited to, early flowering, flowering control for hybrid seed production, seedling vigor, plant size, internode number and distance, root growth, seed size, fruit size, pod size, pod or ear number, seed number per pod or ear, seed mass, enhanced seed filling, reduced seed dispersal, reduced pod dehiscence and lodging resistance. Further yield traits include seed composition, such as carbohydrate content, protein content, oil content and composition, nutritional value, reduction in anti-nutritional compounds, improved processability and better storage stability.

Examples of plants with the above-mentioned traits are non-exhaustively listed in Table A.

Plants that may be treated according to the invention are hybrid plants that already express the characteristic of heterosis or hybrid vigor which results in generally higher yield, vigor, health and resistance towards biotic and abiotic stresses). Such plants are typically made by crossing an inbred male-sterile parent line (the female parent) with another inbred male-fertile parent line (the male parent). Hybrid seed is typically harvested from the male sterile plants and sold to growers. Male sterile plants can sometimes (e.g. in corn) be produced by detasseling, i.e. the mechanical removal of the male reproductive organs (or males flowers) but, more typically, male sterility is the result of genetic determinants in the plant genome. In that case, and especially when seed is the desired product to be harvested from the hybrid plants it is typically useful to ensure that male fertility in the hybrid plants is fully restored. This can be accomplished by ensuring that the male parents have appropriate fertility restorer genes which are capable of restoring the male fertility in hybrid plants that contain the genetic determinants responsible for male-sterility. Genetic determinants for male sterility may be located in the cytoplasm. Examples of cytoplasmic male sterility (CMS) were for instance described in Brassica species (WO 92/05251, WO 95/09910, WO 98/27806, WO 05/002324, WO 06/021972 and U.S. Pat. No. 6,229,072). However, genetic determinants for male sterility can also be located in the nuclear genome. Male sterile plants can also be obtained by plant biotechnology methods such as genetic engineering. A particularly useful means of obtaining male-sterile plants is described in WO 89/10396 in which, for example, a ribonuclease such as barnase is selectively expressed in the tapetum cells in the stamens. Fertility can then be restored by expression in the tapetum cells of a ribonuclease inhibitor such as barstar (e.g. WO 91/02069).

Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may be treated according to the invention are herbicide-tolerant plants, i.e. plants made tolerant to one or more given herbicides. Such plants can be obtained either by genetic transformation, or by selection of plants containing a mutation imparting such herbicide tolerance.

Herbicide-resistant plants are for example glyphosate-tolerant plants, i.e. plants made tolerant to the herbicide glyphosate or salts thereof. Plants can be made tolerant to glyphosate through different means. For example, glyphosate-tolerant plants can be obtained by transforming the plant with a gene encoding the enzyme 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS). Examples of such EPSPS genes are the AroA gene (mutant CT7) of the bacterium Salmonella typhimurium (Comai et al., 1983, Science 221, 370-371), the CP4 gene of the bacterium Agrobacterium sp. (Barry et al., 1992, Curr. Topics Plant Physiol. 7, 139-145), the genes encoding a Petunia EPSPS (Shah et al., 1986, Science 233, 478-481), a Tomato EPSPS (Gasser et al., 1988, J. Biol. Chem. 263, 4280-4289), or an Eleusine EPSPS (WO 01/66704). It can also be a mutated EPSPS as described in for example EP 0837944, WO 00/66746, WO 00/66747 or WO02/26995. Glyphosate-tolerant plants can also be obtained by expressing a gene that encodes a glyphosate oxido-reductase enzyme as described in U.S. Pat. Nos. 5,776,760 and 5,463,175. Glyphosate-tolerant plants can also be obtained by expressing a gene that encodes a glyphosate acetyl transferase enzyme as described in for example WO 02/36782, WO 03/092360, WO 05/012515 and WO 07/024,782. Glyphosate-tolerant plants can also be obtained by selecting plants containing naturally-occurring mutations of the above-mentioned genes, as described in for example WO 01/024615 or WO 03/013226. Plants expressing EPSPS genes that confer glyphosate tolerance are described in e.g. U.S. patent application Ser. Nos. 11/517,991, 10/739,610, 12/139,408, 12/352,532, 11/312,866, 11/315,678, 12/421,292, 11/400,598, 11/651,752, 11/681,285, 11/605,824, 12/468,205, 11/760,570, 11/762,526, 11/769,327, 11/769,255, 11/943,801 or 12/362,774. Plants comprising other genes that confer glyphosate tolerance, such as decarboxylase genes, are described in e.g. U.S. patent application Ser. Nos. 11/588,811, 11/185,342, 12/364,724, 11/185,560 or 12/423,926.

Other herbicide resistant plants are for example plants that are made tolerant to herbicides inhibiting the enzyme glutamine synthase, such as bialaphos, phosphinothricin or glufosinate. Such plants can be obtained by expressing an enzyme detoxifying the herbicide or a mutant glutamine synthase enzyme that is resistant to inhibition, e.g. described in U.S. patent application Ser. No. 11/760,602. One such efficient detoxifying enzyme is an enzyme encoding a phosphinothricin acetyltransferase (such as the bar or pat protein from Streptomyces species). Plants expressing an exogenous phosphinothricin acetyltransferase are for example described in U.S. Pat. Nos. 5,561,236; 5,648,477; 5,646,024; 5,273,894; 5,637,489; 5,276,268; 5,739,082; 5,908,810 and 7,112,665. Further herbicide-tolerant plants are also plants that are made tolerant to the herbicides inhibiting the enzyme hydroxphenylpyruvatedioxygenase (HPPD). Hydroxphenylpyruvatedioxygenases are enzymes that catalyze the reaction in which para-hydroxyphenylpyruvate (HPP) is transformed into homogentisate. Plants tolerant to HPPD-inhibitors can be transformed with a gene encoding a naturally-occurring resistant HPPD enzyme, or a gene encoding a mutated or chimeric HPPD enzyme as described in WO 96/38567, WO 99/24585, WO 99/24586, WO 2009/144079, WO 2002/046387, or U.S. Pat. No. 6,768,044. Tolerance to HPPD-inhibitors can also be obtained by transforming plants with genes encoding certain enzymes enabling the formation of homogentisate despite the inhibition of the native HPPD enzyme by the HPPD-inhibitor. Such plants and genes are described in WO 99/34008 and WO 02/36787. Tolerance of plants to HPPD inhibitors can also be improved by transforming plants with a gene encoding an enzyme having prephenate deshydrogenase (PDH) activity in addition to a gene encoding an HPPD-tolerant enzyme, as described in WO 2004/024928. Further, plants can be made more tolerant to HPPD-inhibitor herbicides by adding into their genome a gene encoding an enzyme capable of metabolizing or degrading HPPD inhibitors, such as the CYP450 enzymes shown in WO 2007/103567 and WO 2008/150473.

Still further herbicide resistant plants are plants that are made tolerant to acetolactate synthase (ALS) inhibitors. Known ALS-inhibitors include, for example, sulfonylurea, imidazolinone, triazolopyrimidines, pryimidinyoxy(thio)benzoates, and/or sulfonylaminocarbonyltriazolinone herbicides. Different mutations in the ALS enzyme (also known as acetohydroxyacid synthase, AHAS) are known to confer tolerance to different herbicides and groups of herbicides, as described for example in Tranel and Wright (2002, Weed Science 50:700-712), but also, in U.S. Pat. Nos. 5,605,011, 5,378,824, 5,141,870, and 5,013,659. The production of sulfonylurea-tolerant plants and imidazolinone-tolerant plants is described in U.S. Pat. Nos. 5,605,011; 5,013,659; 5,141,870; 5,767,361; 5,731,180; 5,304,732; 4,761,373; 5,331,107; 5,928,937; and 5,378,824; and international publication WO 96/33270. Other imidazolinone-tolerant plants are also described in for example WO 2004/040012, WO 2004/106529, WO 2005/020673, WO 2005/093093, WO 2006/007373, WO 2006/015376, WO 2006/024351, and WO 2006/060634. Further sulfonylurea- and imidazolinone-tolerant plants are also described in for example WO 07/024,782 and U.S. Patent Application No. 61/288,958.

Other plants tolerant to imidazolinone and/or sulfonylurea can be obtained by induced mutagenesis, selection in cell cultures in the presence of the herbicide or mutation breeding as described for example for soybeans in U.S. Pat. No. 5,084,082, for rice in WO 97/41218, for sugar beet in U.S. Pat. No. 5,773,702 and WO 99/057965, for lettuce in U.S. Pat. No. 5,198,599, or for sunflower in WO 01/065922.

Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are insect-resistant transgenic plants, i.e. plants made resistant to attack by certain target insects. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation imparting such insect resistance.

An “insect-resistant transgenic plant”, as used herein, includes any plant containing at least one transgene comprising a coding sequence encoding:

-   -   1) an insecticidal crystal protein from Bacillus thuringiensis         or an insecticidal portion thereof, such as the insecticidal         crystal proteins listed by Crickmore et al. (1998, Microbiology         and Molecular Biology Reviews, 62: 807-813), updated by         Crickmore et al. (2005) at the Bacillus thuringiensis toxin         nomenclature, online at:         http://www.lifesci.sussex.ac.uk/Home/Neil_Crickmore/Bt/), or         insecticidal portions thereof, e.g., proteins of the Cry protein         classes Cry1Ab, Cry1Ac, Cry1B, Cry1C, Cry1D, Cry1F, Cry2Ab,         Cry3Aa, or Cry3Bb or insecticidal portions thereof (e.g. EP         1999141 and WO 2007/107302), or such proteins encoded by         synthetic genes as e.g. described in and U.S. patent application         Ser. No. 12/249,016; or     -   2) a crystal protein from Bacillus thuringiensis or a portion         thereof which is insecticidal in the presence of a second other         crystal protein from Bacillus thuringiensis or a portion         thereof, such as the binary toxin made up of the Cry34 and Cry35         crystal proteins (Moellenbeck et al. 2001, Nat. Biotechnol. 19:         668-72; Schnepf et al. 2006, Applied Environm. Microbiol. 71,         1765-1774) or the binary toxin made up of the CryIA or Cry1F         proteins and the Cry2Aa or Cry2Ab or Cry2Ae proteins (U.S.         patent application Ser. No. 12/214,022 and EP 08010791.5); or     -   3) a hybrid insecticidal protein comprising parts of different         insecticidal crystal proteins from Bacillus thuringiensis, such         as a hybrid of the proteins of 1) above or a hybrid of the         proteins of 2) above, e.g., the Cry1A.105 protein produced by         corn event MON89034 (WO 2007/027777); or     -   4) a protein of any one of 1) to 3) above wherein some,         particularly 1 to 10, amino acids have been replaced by another         amino acid to obtain a higher insecticidal activity to a target         insect species, and/or to expand the range of target insect         species affected, and/or because of changes introduced into the         encoding DNA during cloning or transformation, such as the         Cry3Bb1 protein in corn events MON863 or MON88017, or the Cry3A         protein in corn event MIR604; or     -   5) an insecticidal secreted protein from Bacillus thuringiensis         or Bacillus cereus, or an insecticidal portion thereof, such as         the vegetative insecticidal (VIP) proteins listed at:         http://www.lifesci.sussex.ac.uk/home/Neil_Crickmore/Bt/vip.html,         e.g., proteins from the VIP3Aa protein class; or     -   6) a secreted protein from Bacillus thuringiensis or Bacillus         cereus which is insecticidal in the presence of a second         secreted protein from Bacillus thuringiensis or B. cereus, such         as the binary toxin made up of the VIP1A and VIP2A proteins (WO         94/21795); or     -   7) a hybrid insecticidal protein comprising parts from different         secreted proteins from Bacillus thuringiensis or Bacillus         cereus, such as a hybrid of the proteins in 1) above or a hybrid         of the proteins in 2) above; or     -   8) a protein of any one of 5) to 7) above wherein some,         particularly 1 to 10, amino acids have been replaced by another         amino acid to obtain a higher insecticidal activity to a target         insect species, and/or to expand the range of target insect         species affected, and/or because of changes introduced into the         encoding DNA during cloning or transformation (while still         encoding an insecticidal protein), such as the VIP3Aa protein in         cotton event COT102; or     -   9) a secreted protein from Bacillus thuringiensis or Bacillus         cereus which is insecticidal in the presence of a crystal         protein from Bacillus thuringiensis, such as the binary toxin         made up of VIP3 and CryIA or Cry1F (U.S. Patent Appl. No.         61/126,083 and 61/195,019), or the binary toxin made up of the         VIP3 protein and the Cry2Aa or Cry2Ab or Cry2Ae proteins (U.S.         patent application Ser. No. 12/214,022 and EP 08010791.5).     -   10) a protein of 9) above wherein some, particularly 1 to 10,         amino acids have been replaced by another amino acid to obtain a         higher insecticidal activity to a target insect species, and/or         to expand the range of target insect species affected, and/or         because of changes introduced into the encoding DNA during         cloning or transformation (while still encoding an insecticidal         protein)

Of course, an insect-resistant transgenic plant, as used herein, also includes any plant comprising a combination of genes encoding the proteins of any one of the above classes 1 to 10. In one embodiment, an insect-resistant plant contains more than one transgene encoding a protein of any one of the above classes 1 to 10, to expand the range of target insect species affected when using different proteins directed at different target insect species, or to delay insect resistance development to the plants by using different proteins insecticidal to the same target insect species but having a different mode of action, such as binding to different receptor binding sites in the insect.

An “insect-resistant transgenic plant”, as used herein, further includes any plant containing at least one transgene comprising a sequence producing upon expression a double-stranded RNA which upon ingestion by a plant insect pest inhibits the growth of this insect pest, as described e.g. in WO 2007/080126, WO 2006/129204, WO 2007/074405, WO 2007/080127 and WO 2007/035650.

Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are tolerant to abiotic stresses. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation imparting such stress resistance. Particularly useful stress tolerance plants include:

-   -   1) plants which contain a transgene capable of reducing the         expression and/or the activity of poly(ADP-ribose) polymerase         (PARP) gene in the plant cells or plants as described in WO         00/04173, WO/2006/045633, EP 04077984.5, or EP 06009836.5.     -   2) plants which contain a stress tolerance enhancing transgene         capable of reducing the expression and/or the activity of the         PARG encoding genes of the plants or plants cells, as described         e.g. in WO 2004/090140.     -   3) plants which contain a stress tolerance enhancing transgene         coding for a plant-functional enzyme of the nicotineamide         adenine dinucleotide salvage synthesis pathway including         nicotinamidase, nicotinate phosphoribosyltransferase, nicotinic         acid mononucleotide adenyl transferase, nicotinamide adenine         dinucleotide synthetase or nicotine amide         phosphorybosyltransferase as described e.g. in EP 04077624.7, WO         2006/133827, PCT/EP07/002,433, EP 1999263, or WO 2007/107326.

Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention show altered quantity, quality and/or storage-stability of the harvested product and/or altered properties of specific ingredients of the harvested product such as:

-   -   1) transgenic plants which synthesize a modified starch, which         in its physical-chemical characteristics, in particular the         amylose content or the amylose/amylopectin ratio, the degree of         branching, the average chain length, the side chain         distribution, the viscosity behaviour, the gelling strength, the         starch grain size and/or the starch grain morphology, is changed         in comparison with the synthesised starch in wild type plant         cells or plants, so that this is better suited for special         applications. Said transgenic plants synthesizing a modified         starch are disclosed, for example, in EP 0571427, WO 95/04826,         EP 0719338, WO 96/15248, WO 96/19581, WO 96/27674, WO 97/11188,         WO 97/26362, WO 97/32985, WO 97/42328, WO 97/44472, WO 97/45545,         WO 98/27212, WO 98/40503, WO99/58688, WO 99/58690, WO 99/58654,         WO 00/08184, WO 00/08185, WO 00/08175, WO 00/28052, WO 00/77229,         WO 01/12782, WO 01/12826, WO 02/101059, WO 03/071860, WO         2004/056999, WO 2005/030942, WO 2005/030941, WO 2005/095632, WO         2005/095617, WO 2005/095619, WO 2005/095618, WO 2005/123927, WO         2006/018319, WO 2006/103107, WO 2006/108702, WO 2007/009823, WO         00/22140, WO 2006/063862, WO 2006/072603, WO 02/034923, EP         06090134.5, EP 06090228.5, EP 06090227.7, EP 07090007.1, EP         07090009.7, WO 01/14569, WO 02/79410, WO 03/33540, WO         2004/078983, WO 01/19975, WO 95/26407, WO 96/34968, WO 98/20145,         WO 99/12950, WO 99/66050, WO 99/53072, U.S. Pat. No. 6,734,341,         WO 00/11192, WO 98/22604, WO 98/32326, WO 01/98509, WO 01/98509,         WO 2005/002359, U.S. Pat. Nos. 5,824,790, and 6,013,861, WO         94/04693, WO 94/09144, WO 94/11520, WO 95/35026, WO 97/20936     -   2) transgenic plants which synthesize non starch carbohydrate         polymers or which synthesize non starch carbohydrate polymers         with altered properties in comparison to wild type plants         without genetic modification. Examples are plants producing         polyfructose, especially of the inulin and levan-type, as         disclosed in EP 0663956, WO 96/01904, WO 96/21023, WO 98/39460,         and WO 99/24593, plants producing alpha-1,4-glucans as disclosed         in WO 95/31553, US 2002031826, U.S. Pat. Nos. 6,284,479, and         5,712,107, WO 97/47806, WO 97/47807, WO 97/47808 and WO         00/14249, plants producing alpha-1,6 branched alpha-1,4-glucans,         as disclosed in WO 00/73422, plants producing alternan, as         disclosed in e.g. WO 00/47727, WO 00/73422, EP 06077301.7, U.S.         Pat. No. 5,908,975 and EP 0728213,     -   3) transgenic plants which produce hyaluronan, as for example         disclosed in WO 2006/032538, WO 2007/039314, WO 2007/039315, WO         2007/039316, JP 2006304779, and WO 2005/012529.     -   4) transgenic plants or hybrid plants, such as onions with         characteristics such as ‘high soluble solids content’, ‘low         pungency’ (LP) and/or ‘long storage’ (LS), as described in U.S.         patent application Ser. No. 12/020,360 and 61/054,026.

Plants or plant cultivars (that can be obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are plants, such as cotton plants, with altered fiber characteristics. Such plants can be obtained by genetic transformation, or by selection of plants contain a mutation imparting such altered fiber characteristics and include:

-   -   a) Plants, such as cotton plants, containing an altered form of         cellulose synthase genes as described in WO 98/00549     -   b) Plants, such as cotton plants, containing an altered form of         rsw2 or rsw3 homologous nucleic acids as described in WO         2004/053219     -   c) Plants, such as cotton plants, with increased expression of         sucrose phosphate synthase as described in WO 01/17333     -   d) Plants, such as cotton plants, with increased expression of         sucrose synthase as described in WO 02/45485     -   e) Plants, such as cotton plants, wherein the timing of the         plasmodesmatal gating at the basis of the fiber cell is altered,         e.g. through downregulation of fiber-selective β-1,3-glucanase         as described in WO 2005/017157, or as described in EP 08075514.3         or U.S. Patent Appl. No. 61/128,938     -   f) Plants, such as cotton plants, having fibers with altered         reactivity, e.g. through the expression of         N-acetylglucosaminetransferase gene including nodC and chitin         synthase genes as described in WO 2006/136351

Plants or plant cultivars (that can be obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are plants, such as oilseed rape or related Brassica plants, with altered oil profile characteristics. Such plants can be obtained by genetic transformation, or by selection of plants contain a mutation imparting such altered oil profile characteristics and include:

-   -   a) Plants, such as oilseed rape plants, producing oil having a         high oleic acid content as described e.g. in U.S. Pat. Nos.         5,969,169, 5,840,946 or 6,323,392 or 6,063,947     -   b) Plants such as oilseed rape plants, producing oil having a         low linolenic acid content as described in U.S. Pat. Nos.         6,270,828, 6,169,190, or 5,965,755     -   c) Plant such as oilseed rape plants, producing oil having a low         level of saturated fatty acids as described e.g. in U.S. Pat.         No. 5,434,283 or U.S. patent application Ser. No. 12/668,303

Plants or plant cultivars (that can be obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are plants, such as oilseed rape or related Brassica plants, with altered seed shattering characteristics. Such plants can be obtained by genetic transformation, or by selection of plants contain a mutation imparting such altered seed shattering characteristics and include plants such as oilseed rape plants with delayed or reduced seed shattering as described in U.S. Patent Appl. No. 61/135,230 WO09/068,313 and WO10/006,732. Particularly useful transgenic plants which may be treated according to the invention are plants containing transformation events, or combination of transformation events, that are the subject of petitions for non-regulated status, in the United States of America, to the Animal and Plant Health Inspection Service (APHIS) of the United States Department of Agriculture (USDA) whether such petitions are granted or are still pending. At any time this information is readily available from APHIS (4700 River Road Riverdale, Md. 20737, USA), for instance on its internet site (URL http://www.aphis.usda.gov/brs/not_reg.html). On the filing date of this application the petitions for nonregulated status that were pending with APHIS or granted by APHIS were those listed in table B which contains the following information:

-   -   Petition: the identification number of the petition. Technical         descriptions of the transformation events can be found in the         individual petition documents which are obtainable from APHIS,         for example on the APHIS website, by reference to this petition         number. These descriptions are herein incorporated by reference.     -   Extension of Petition: reference to a previous petition for         which an extension is requested.     -   Institution: the name of the entity submitting the petition.     -   Regulated article: the plant species concerned.     -   Transgenic phenotype: the trait conferred to the plants by the         transformation event.     -   Transformation event or line: the name of the event or events         (sometimes also designated as lines or lines) for which         nonregulated status is requested.     -   APHIS documents: various documents published by APHIS in         relation to the Petition and which can be requested with APHIS.

Additional particularly useful plants containing single transformation events or combinations of transformation events are listed for example in the databases from various national or regional regulatory agencies (see for example http://gmoinfo.jrc.it/gmp_browse.aspx and http://www.agbios.com/dbase.php).

Further particularly transgenic plants include plants containing a transgene in an agronomically neutral or beneficial position as described in any of the patent publications listed in Table C.

TABLE A Trait Reference Water use efficiency WO 2000/073475 Nitrogen use efficiency WO 1995/009911 WO 2007/076115 WO 1997/030163 WO 2005/103270 WO 2007/092704 WO 2002/002776 Improved photosynthesis WO 2008/056915 WO 2004/101751 Nematode resistance WO 1995/020669 WO 2003/033651 WO 2001/051627 WO 1999/060141 WO 2008/139334 WO 1998/012335 WO 2008/095972 WO 1996/030517 WO 2006/085966 WO 1993/018170 Reduced pod dehiscence WO 2006/009649 WO 1997/013865 WO 2004/113542 WO 1996/030529 WO 1999/015680 WO 1994/023043 WO 1999/000502 Aphid resistance WO 2006/125065 WO 2008/067043 WO 1997/046080 WO 2004/072109 Sclerotinia resistance WO 2006/135717 WO 2005/000007 WO 2006/055851 WO 2002/099385 WO 2005/090578 WO 2002/061043 Botrytis resistance WO 2006/046861 WO 2002/085105 Bremia resistance US 20070022496 WO 2004/049786 WO 2000/063432 Erwinia resistance WO 2004/049786 Closterovirus resistance WO 2007/073167 WO 2002/022836 WO 2007/053015 Stress tolerance (including WO 2010/019838 WO2008/002480 drought tolerance) WO 2009/049110 WO2005/033318 Tobamovirus resistance WO 2006/038794

TABLE B Petitions of Nonregulated Status Granted or Pending by APHIS as of Mar. 31, 2010 Applicant Documents Extension of Petition Regulated Transgenic Transformation Petition Number *** Institution Article Phenotype Event or Line Petitions for Nonregulated Status Pending 10-070-01p Virginia Tech Peanut Sclerotinia blight N70, P39, and resistant W171 09-349-01p Dow Soybean Herbicide Tolerant DAS-68416-4 AgroSciences 09-328-01p Bayer Crop Soybean Herbicide Tolerant FG72 Science 09-233-01p Dow Corn Herbicide Tolerant DAS-40278-9 09-201-01p Monsanto Soybean MON-877Ø5-6 09-183-01p Monsanto Soybean MON-87769 09-082-01p Monsanto Soybean Lepidopteran resistant MON 87701 09-063-01p Stine Seed Corn Glyphosate tolerant HCEM485 09-055-01p Monsanto Corn Drought Tolerant MON 87460 09-015-01p BASF Plant Soybean Herbicide Tolerant BPS-CV127-9 Science, LLC Soybean 08-366-01p ArborGen Eucalyptus Freeze Tolerant, ARB-FTE1-08 Fertility Altered 08-340-01p Bayer Cotton Glufosinate Tolerant, T304-40XGHB119 Insect Resistant 08-338-01p Pioneer Corn Male Sterile, Fertility DP-32138-1 Restored, Visual Marker 08-315-01p Florigene Rose Altered Flower Color IFD-524Ø1-4 and IFD-529Ø1-9 07-253-01p Syngenta Corn Lepidopteran resistant MIR-162 Maize 07-108-01p Syngenta Cotton Lepidopteran Resistant COT67B 06-354-01p Pioneer Soybean High Oleic Acid DP-3Ø5423-1 05-280-01p Syngenta Corn Thermostable alpha- 3272 amylase 04-110-01p Monsanto & Alfalfa Glyphosate Tolerant J101, J163 Forage Genetics 03-104-01p Monsanto & Creeping Glyphosate Tolerant ASR368 Scotts bentgrass Petitions for Nonregulated Status Granted 07-152-01p Pioneer Corn glyphosate & DP-098140-6 Imidazolinone tolerant 04-337-01p University of Papaya Papaya Ringspot Virus X17-2 Florida Resistant 06-332-01p Bayer Cotton Glyphosate tolerant GHB614 CropScience 06-298-01p Monsanto Corn European Corn Borer MON 89034 resistant 06-271-01p Pioneer Soybean Glyphosate & 356043 acetolactate synthase (DP-356Ø43-5) tolerant 06-234-01p 98-329-01p Bayer Rice Phosphinothricin LLRICE601 CropScience tolerant 06-178-01p Monsanto Soybean Glyphosate tolerant MON 89788 04-362-01p Syngenta Corn Corn Rootworm MIR604 Protected 04-264-01p ARS Plum Plum Pox Virus C5 Resistant 04-229-01p Monsanto Corn High Lysine LY038 04-125-01p Monsanto Corn Corn Rootworm 88017 Resistant 04-086-01p Monsanto Cotton Glyphosate Tolerant MON 88913 03-353-01p Dow Corn Corn Rootworm 59122 Resistant 03-323-01p Monsanto Sugar Glyphosate Tolerant H7-1 Beet 03-181-01p 00-136-01p Dow Corn Lepidopteran Resistant TC-6275 & Phosphinothricin tolerant 03-155-01p Syngenta Cotton Lepidopteran Resistant COT 102 03-036-01p Mycogen/Dow Cotton Lepidopteran Resistant 281-24-236 03-036-02p Mycogen/Dow Cotton Lepidopteran Resistant 3006-210-23 02-042-01p Aventis Cotton Phosphinothericin LLCotton25 tolerant 01-324-01p 98-216-01p Monsanto Rapeseed Glyphosate tolerant RT200 01-206-01p 98-278-01p Aventis Rapeseed Phosphinothricin MS1 & RF1/RF2 tolerant & pollination control 01-206-02p 97-205-01p Aventis Rapeseed Phosphinothricin Topas 19/2 tolerant 01-137-01p Monsanto Corn Corn Rootworm MON 863 Resistant 01-121-01p Vector Tobacco Reduced nicotine Vector 21-41 00-342-01p Monsanto Cotton Lepidopteran resistant Cotton Event 15985 00-136-01p Mycogen c/o Corn Lepidopteran resistant Line 1507 Dow & Pioneer phosphinothricin tolerant 00-011-01p 97-099-01p Monsanto Corn Glyphosate tolerant NK603 99-173-01p 97-204-01p Monsanto Potato PLRV & CPB resistant RBMT22-82 98-349-01p 95-228-01p AgrEvo Corn Phosphinothricin MS6 tolerant and Male sterile 98-335-01p U. of Flax Tolerant to soil CDC Triffid Saskatchewan residues of sulfonyl urea herbicide 98-329-01p AgrEvo Rice Phosphinothricin LLRICE06, tolerant LLRICE62 98-278-01p AgrEvo Rapeseed Phosphinothricin MS8 & RF3 tolerant & Pollination control 98-238-01p AgrEvo Soybean Phosphinothricin GU262 tolerant 98-216-01p Monsanto Rapeseed Glyphosate tolerant RT73 98-173-01p Novartis Seeds & Beet Glyphosate tolerant GTSB77 Monsanto 98-014-01p 96-068-01p AgrEvo Soybean Phosphinothricin A5547-127 tolerant 97-342-01p Pioneer Corn Male sterile & 676, 678, 680 Phosphinothricin tolerant 97-339-01p Monsanto Potato CPB & PVY resistant RBMT15-101, SEMT15-02, SEMT15-15 97-336-01p AgrEvo Beet Phosphinothricin T-120-7 tolerant 97-287-01p Monsanto Tomato Lepidopteran resistant 5345 97-265-01p AgrEvo Corn Phosphinothricin CBH-351 tolerant & Lep. resistant 97-205-01p AgrEvo Rapeseed Phosphinothricin T45 tolerant 97-204-01p Monsanto Potato CPB & PLRV resistant RBMT21-129 & RBMT21-350 97-148-01p Bejo Cichorium Male sterile RM3-3, RM3-4, intybus RM3-6 97-099-01p Monsanto Corn Glyphosate tolerant GA21 97-013-01p Calgene Cotton Bromoxynil tolerant & Events 31807 & Lepidopteran resistant 31808 97-008-01p Du Pont Soybean Oil profile altered G94-1, G94-19, G- 168 96-317-01p Monsanto Corn Glyphosate tolerant & MON802 ECB resistant 96-291-01p DeKalb Corn European Corn Borer DBT418 resistant 96-248-01p 92-196-01p Calgene Tomato Fruit ripening altered 1 additional FLAVRSAVR line 96-068-01p AgrEvo Soybean Phosphinothricin W62, W98, A2704- tolerant 12, A2704-21, A5547-35 96-051-01p Cornell U Papaya PRSV resistant 55-1, 63-1 96-017-01p 95-093-01p Monsanto Corn European Corn Borer MON809 & resistant MON810 95-352-01p Asgrow Squash CMV, ZYMV, WMV2 CZW-3 resistant 95-338-01p Monsanto Potato CPB resistant SBT02-5 & -7, ATBT04-6 &-27, -30, -31, -36 95-324-01p Agritope Tomato Fruit ripening altered 35 1 N 95-256-01p Du Pont Cotton Sulfonylurea tolerant 19-51a 95-228-01p Plant Genetic Corn Male sterile MS3 Systems 95-195-01p Northrup King Corn European Corn Borer Bt11 resistant 95-179-01p 92-196-01p Calgene Tomato Fruit ripening altered 2 additional FLAVRSAVR lines 95-145-01p DeKalb Corn Phosphinothricin B16 tolerant 95-093-01p Monsanto Corn Lepidopteran resistant MON 80100 95-053-01p Monsanto Tomato Fruit ripening altered 8338 95-045-01p Monsanto Cotton Glyphosate tolerant 1445, 1698 95-030-01p 92-196-01p Calgene Tomato Fruit ripening altered 20 additional FLAVRSAVR lines 94-357-01p AgrEvo Corn Phosphinothricin T14, T25 tolerant 94-319-01p Ciba Seeds Corn Lepidopteran resistant Event 176 94-308-01p Monsanto Cotton Lepidopteran resistant 531, 757, 1076 94-290-01p Zeneca & Tomato Fruit polygalacturonase B, Da, F Petoseed level decreased 94-257-01p Monsanto Potato Coleopteran resistant BT6, BT10, BT12, BT16, BT17, BT18, BT23 94-230-01p 92-196-01p Calgene Tomato Fruit ripening altered 9 additional FLAVRSAVR lines 94-228-01p DNA Plant Tech Tomato Fruit ripening altered 1345-4 94-227-01p 92-196-01p Calgene Tomato Fruit ripening altered Line N73 1436-111 94-090-01p Calgene Rapeseed Oil profile altered pCGN3828- 212/86- 18 & 23 93-258-01p Monsanto Soybean Glyphosate tolerant 40-3-2 93-196-01p Calgene Cotton Bromoxynil tolerant BXN 92-204-01p Upjohn Squash WMV2 & ZYMV ZW-20 resistant 92-196-01p Calgene Tomato Fruit ripening altered FLAVR SAVR NOTE: To obtain the most up-to-date list of Crops No Longer Regulated, please look at the Current Status of Petitions. This list is automatically updated and reflects all petitions received to date by APHIS, including petitions pending, withdrawn, or approved. Abbreviations: CMV—cucumber mosaic virus; CPB—colorado potato beetle; PLRV—potato leafroll virus; PRSV—papaya ringspot virus; PVY—potato virus Y; WMV2—watermelon mosaic virus 2 ZYMV—zucchini yellow mosaic virus *** Extension of Petition Number: Under 7CFR 340.6(e) a person may request that APHIS extend a determination of non-regulated status to other organisms based on their similarity of the previously deregulated article. This column lists the previously granted petition of that degregulated article. **** Preliminary EA: The Environmental Assessment initially available for Public comment prior to finalization.

TABLE C Plant species Event Trait Patent reference Corn PV-ZMGT32 Glyphosate tolerance US 2007-056056 (NK603) Corn MIR604 Insect resistance (Cry3a055) EP 1 737 290 Corn LY038 High lysine content U.S. Pat. No. 7,157,281 Corn 3272 Self processing corn (alpha- US 2006-230473 amylase) Corn PV-ZMIR13 Insect resistance (Cry3Bb) US 2006-095986 (MON863) Corn DAS-59122-7 Insect resistance US 2006-070139 (Cry34Ab1/Cry35Ab1) Corn TC1507 Insect resistance (Cry1F) U.S. Pat. No. 7,435,807 Corn MON810 Insect resistance (Cry1Ab) US 2004-180373 Corn VIP1034 Insect resistance WO 03/052073 Corn B16 Glufosinate resistance US 2003-126634 Corn GA21 Glyphosate resistance U.S. Pat. No. 6,040,497 Corn GG25 Glyphosate resistance U.S. Pat. No. 6,040,497 Corn GJ11 Glyphosate resistance U.S. Pat. No. 6,040,497 Corn FI117 Glyphosate resistance U.S. Pat. No. 6,040,497 Corn GAT-ZM1 Glufosinate tolerance WO 01/51654 Corn MON87460 Drought tolerance WO 2009/111263 Corn DP-098140-6 Glyphosate tolerance/ALS WO 2008/112019 inhibitor tolerance Wheat Event 1 Fusarium resistance CA 2561992 (trichothecene 3-O- acetyltransferase) Sugar beet T227-1 Glyphosate tolerance US 2004-117870 Sugar beet H7-1 Glyphosate tolerance WO 2004-074492 Soybean MON89788 Glyphosate tolerance US 2006-282915 Soybean A2704-12 Glufosinate tolerance WO 2006/108674 Soybean A5547-35 Glufosinate tolerance WO 2006/108675 Soybean DP-305423-1 High oleic acid/ALS inhibitor WO 2008/054747 tolerance Rice GAT-OS2 Glufosinate tolerance WO 01/83818 Rice GAT-OS3 Glufosinate tolerance US 2008-289060 Rice PE-7 Insect resistance (Cry1Ac) WO 2008/114282 Oilseed rape MS-B2 Male sterility WO 01/31042 Oilseed rape MS-BN1/RF-BN1 Male sterility/restoration WO 01/41558 Oilseed rape RT73 Glyphosate resistance WO 02/36831 Cotton CE43-67B Insect resistance (Cry1Ab) WO 2006/128573 Cotton CE46-02A Insect resistance (Cry1Ab) WO 2006/128572 Cotton CE44-69D Insect resistance (Cry1Ab) WO 2006/128571 Cotton 1143-14A Insect resistance (Cry1Ab) WO 2006/128569 Cotton 1143-51B Insect resistance (Cry1Ab) WO 2006/128570 Cotton T342-142 Insect resistance (Cry1Ab) WO 2006/128568 Cotton event3006-210-23 Insect resistance (Cry1Ac) WO 2005/103266 Cotton PV-GHGT07 (1445) Glyphosate tolerance US 2004-148666 Cotton MON88913 Glyphosate tolerance WO 2004/072235 Cotton EE-GH3 Glyphosate tolerance WO 2007/017186 Cotton T304-40 Insect-resistance (Cry1Ab) WO2008/122406 Cotton Cot202 Insect resistance (VIP3) US 2007-067868 Cotton LLcotton25 Glufosinate resistance WO 2007/017186 Cotton EE-GH5 Insect resistance (Cry1Ab) WO 2008/122406 Cotton event 281-24-236 Insect resistance (Cry1F) WO 2005/103266 Cotton Cot102 Insect resistance (Vip3A) US 2006-130175 Cotton MON 15985 Insect resistance (Cry1A/ US 2004-250317 Cry2Ab) Bent Grass Asr-368 Glyphosate tolerance US 2006-162007 Brinjal EE-1 Insect resistance (Cry1Ac) WO 2007/091277

Among the diseases of plants or crops that can be controlled by the method according to the invention, mention can be made of:

Powdery mildew diseases such as:

-   -   Blumeria diseases, caused for example by Blumeria graminis;     -   Podosphaera diseases, caused for example by Podosphaera         leucotricha;     -   Sphaerotheca diseases, caused for example by Sphaerotheca         fuliginea;     -   Uncinula diseases, caused for example by Uncinula necator;         Rust diseases such as:     -   Gymnosporangium diseases, caused for example by Gymnosporangium         sabinae;     -   Hemileia diseases, caused for example by Hemileia vastatrix;     -   Phakopsora diseases, caused for example by Phakopsora pachyrhizi         or Phakopsora meibomiae;     -   Puccinia diseases, caused for example by Puccinia recondite,         Puccinia graminis or Puccinia striiformis;     -   Uromyces diseases, caused for example by Uromyces         appendiculatus;         Oomycete diseases such as:     -   Albugo diseases caused for example by Albugo candida;     -   Bremia diseases, caused for example by Bremia lactucae;     -   Peronospora diseases, caused for example by Peronospora pisi         or P. brassicae;     -   Phytophthora diseases, caused for example by Phytophthora         infestans;     -   Plasmopara diseases, caused for example by Plasmopara viticola;     -   Pseudoperonospora diseases, caused for example by         Pseudoperonospora humuli or Pseudoperonospora cubensis;     -   Pythium diseases, caused for example by Pythium ultimum;         Leafspot, leaf blotch and leaf blight diseases such as:     -   Alternaria diseases, caused for example by Alternaria solani;     -   Cercospora diseases, caused for example by Cercospora beticola;     -   Cladiosporum diseases, caused for example by Cladiosporium         cucumerinum;     -   Cochliobolus diseases, caused for example by Cochliobolus         sativus (Conidiaform: Drechslera, Syn: Helminthosporium) or         Cochliobolus miyabeanus;     -   Colletotrichum diseases, caused for example by Colletotrichum         lindemuthanium;     -   Cycloconium diseases, caused for example by Cycloconium         oleaginum;     -   Diaporthe diseases, caused for example by Diaporthe citri;     -   Elsinoe diseases, caused for example by Elsinoe fawcettii;     -   Gloeosporium diseases, caused for example by Gloeosporium         laeticolor;     -   Glomerella diseases, caused for example by Glomerella cingulata;     -   Guignardia diseases, caused for example by Guignardia bidwelli;     -   Leptosphaeria diseases, caused for example by Leptosphaeria         maculans; Leptosphaeria nodorum;     -   Magnaporthe diseases, caused for example by Magnaporthe grisea;     -   Mycosphaerella diseases, caused for example by Mycosphaerella         graminicola; Mycosphaerella arachidicola; Mycosphaerella         fijiensis;     -   Phaeosphaeria diseases, caused for example by Phaeosphaeria         nodorum;     -   Pyrenophora diseases, caused for example by Pyrenophora teres,         or Pyrenophora tritici repentis;     -   Ramularia diseases, caused for example by Ramularia collo-cygni,         or Ramularia areola;     -   Rhynchosporium diseases, caused for example by Rhynchosporium         secalis;     -   Septoria diseases, caused for example by Septoria apii or         Septoria lycopercisi;     -   Typhula diseases, caused for example by Typhula incamata;     -   Venturia diseases, caused for example by Venturia inaequalis;         Root, Sheath and stem diseases such as:     -   Corticium diseases, caused for example by Corticium graminearum;     -   Fusarium diseases, caused for example by Fusarium oxysporum;     -   Gaeumannomyces diseases, caused for example by Gaeumannomyces         graminis;     -   Rhizoctonia diseases, caused for example by Rhizoctonia solani;     -   Sarocladium diseases caused for example by Sarocladium oryzae;     -   Sclerotium diseases caused for example by Sclerotium oryzae;     -   Tapesia diseases, caused for example by Tapesia acuformis;     -   Thielaviopsis diseases, caused for example by Thielaviopsis         basicola;         Ear and panicle diseases such as:

Alternaria diseases, caused for example by Alternaria spp.;

-   -   Aspergillus diseases, caused for example by Aspergillus flavus;     -   Cladosporium diseases, caused for example by Cladosporium spp.;     -   Claviceps diseases, caused for example by Claviceps purpurea;     -   Fusarium diseases, caused for example by Fusarium culmorum;     -   Gibberella diseases, caused for example by Gibberella zeae;     -   Monographella diseases, caused for example by Monographella         nivalis;         Smut and bunt diseases such as:     -   Sphacelotheca diseases, caused for example by Sphacelotheca         reiliana;     -   Tilletia diseases, caused for example by Tilletia caries;     -   Urocystis diseases, caused for example by Urocystis occulta;     -   Ustilago diseases, caused for example by Ustilago nuda;         Fruit rot and mould diseases such as:     -   Aspergillus diseases, caused for example by Aspergillus flavus;     -   Botrytis diseases, caused for example by Botrytis cinerea;     -   Penicillium diseases, caused for example by Penicillium         expansum;     -   Rhizopus diseases caused by example by Rhizopus stolonifer     -   Sclerotinia diseases, caused for example by Sclerotinia         sclerotiorum;     -   Verticilium diseases, caused for example by Verticilium         alboatrum;         Seed and soilborne decay, mould, wilt, rot and damping-off         diseases:     -   Alternaria diseases, caused for example by Alternaria         brassicicola     -   Aphanomyces diseases, caused for example by Aphanomyces         euteiches     -   Ascochyta diseases, caused for example by Ascochyta lentis     -   Aspergillus diseases, caused for example by Aspergillus flavus     -   Cladosporium diseases, caused for example by Cladosporium         herbarum     -   Cochliobolus diseases, caused for example by Cochliobolus         sativus     -   (Conidiaform: Drechslera, Bipolaris Syn: Helminthosporium);     -   Colletotrichum diseases, caused for example by Colletotrichum         coccodes;     -   Fusarium diseases, caused for example by Fusarium culmorum;     -   Gibberella diseases, caused for example by Gibberella zeae;     -   Macrophomina diseases, caused for example by Macrophomina         phaseolina     -   Monographella diseases, caused for example by Monographella         nivalis;     -   Penicillium diseases, caused for example by Penicillium expansum     -   Phoma diseases, caused for example by Phoma lingam     -   Phomopsis diseases, caused for example by Phomopsis sojae;     -   Phytophthora diseases, caused for example by Phytophthora         cactorum;     -   Pyrenophora diseases, caused for example by Pyrenophora graminea     -   Pyricularia diseases, caused for example by Pyricularia oryzae;     -   Pythium diseases, caused for example by Pythium ultimum;     -   Rhizoctonia diseases, caused for example by Rhizoctonia solani;     -   Rhizopus diseases, caused for example by Rhizopus oryzae     -   Sclerotium diseases, caused for example by Sclerotium rolfsii;     -   Septoria diseases, caused for example by Septoria nodorum;     -   Typhula diseases, caused for example by Typhula incarnata;     -   Verticillium diseases, caused for example by Verticillium         dahliae;         Canker, broom and dieback diseases such as:     -   Nectria diseases, caused for example by Nectria galligena;         Blight diseases such as:     -   Monilinia diseases, caused for example by Monilinia laxa;         Leaf blister or leaf curl diseases such as:     -   Exobasidium diseases caused for example by Exobasidium vexans     -   Taphrina diseases, caused for example by Taphrina deformans;         Decline diseases of wooden plants such as:     -   Esca diseases, caused for example by Phaemoniella clamydospora;     -   Eutypa dyeback, caused for example by Eutypa lata;     -   Ganoderma diseases caused for example by Ganoderma boninense;     -   Rigidoporus diseases caused for example by Rigidoporus lignosus         Diseases of Flowers and Seeds such as     -   Botrytis diseases caused for example by Botrytis cinerea;         Diseases of Tubers such as     -   Rhizoctonia diseases caused for example by Rhizoctonia solani;     -   Helminthosporium diseases caused for example by Helminthosporium         solani;         Club root diseases such as     -   Plasmodiophora diseases, cause for example by Plamodiophora         brassicae.         Diseases caused by Bacterial Organisms such as     -   Xanthomonas species for example Xanthomonas campestris pv.         oryzae;     -   Pseudomonas species for example Pseudomonas syringae pv.         lachrymans;     -   Erwinia species for example Erwinia amylovora.

The composition according to the invention may also be used against fungal diseases liable to grow on or inside timber. The term “timber” means all types of species of wood, and all types of working of this wood intended for construction, for example solid wood, high-density wood, laminated wood, and plywood. The method for treating timber according to the invention mainly consists in contacting one or more compounds according to the invention or a composition according to the invention; this includes for example direct application, spraying, dipping, injection or any other suitable means.

The dose of active compound usually applied in the method of treatment according to the invention is generally and advantageously from 10 to 800 g/ha, preferably from 50 to 300 g/ha for applications in foliar treatment. The dose of active substance applied is generally and advantageously from 2 to 200 g per 100 kg of seed, preferably from 3 to 150 g per 100 kg of seed in the case of seed treatment.

It is clearly understood that the doses indicated herein are given as illustrative examples of the method according to the invention. A person skilled in the art will know how to adapt the application doses, notably according to the nature of the plant or crop to be treated.

The compounds or mixtures according to the invention can also be used for the preparation of composition useful to curatively or preventively treat human or animal fungal diseases such as, for example, mycoses, dermatoses, trichophyton diseases and candidiases or diseases caused by Aspergillus spp., for example Aspergillus fumigatus.

The various aspects of the invention will now be illustrated with reference to the following table of compound examples and the following preparation or efficacy examples.

Table 1 illustrates in a non-limiting manner examples of compounds of formula (I) according to the invention.

In table 1, M+H (Apcl+) means the molecular ion peak plus 1 a.m.u. (atomic mass unit) as observed in mass spectroscopy via positive atmospheric pressure chemical ionisation.

In table 1, the log P values were determined in accordance with EEC Directive 79/831 Annex V.A8 by HPLC (High Performance Liquid Chromatography) on a reversed-phase column (C 18), using the method described below:

Temperature: 40° C.; Mobile phases: 0.1% aqueous formic acid and acetonitrile; linear gradient from 10% acetonitrile to 90% acetonitrile.

Calibration was carried out using unbranched alkan-2-ones (comprising 3 to 16 carbon atoms) with known log P values (determination of the log P values by the retention times using linear interpolation between two successive alkanones). lambda-max-values were determined using UV-spectra from 200 nm to 400 nm and the peak values of the chromatographic signals.

TABLE 1 Compound X¹ X² T Z¹ Z² Z³ R¹ R² R³ R⁴ Y R⁵ logP Mass M + H 1 Cl F O H Me H H H H H CR⁵ H 2.49 314 2 F F O H Me H H H H H CR⁵ H 2.33 298 3 F F O H CN H H H H H CR⁵ H 2.07 4 Cl F O H CN H H H H H CR⁵ H 2.20 5 Cl F O Me H H Me H H H CR⁵ Me 3.02 342 6 F F O Me H H Me H H H CR⁵ Me 2.84 326 7 Cl F O H CN H F H H F CR⁵ H 2.31 8 F F O H CN H F H H F CR⁵ H 2.01 9 F F O H Me Me F H H H CR⁵ F 4.19 348 10 Cl F O H Me Me F H H H CR⁵ F 3.89 364 11 F F O cyanomethyl H H Et H H H CR⁵ H 2.68 351 12 F F O cyclobutyl H H Et H H H CR⁵ H 3.63 366 13 F F O Et H H Et H H H CR⁵ H 3.13 340 14 F F O i-Pr ⁽¹⁾ H H Et H H H CR⁵ H 3.39 354 15 F F O Me H H Et H H H CR⁵ H 2.81 326 16 F F O allyl H H Et H H H CR⁵ H 3.36 352 17 F F O propargyl H H Et H H H CR⁵ H 3.10 350 18 F F S Me Me H Cl H H H CR⁵ H 3.44 362 19 Cl F O H CF₃ H Cl H H H CR⁵ H 3.33 402 20 Cl F O H Me H Cl H H H CR⁵ H 2.92 348 21 Cl F O H H H Cl H H H CR⁵ H 2.69 334 22 Cl F O H Me Me Cl H H H CR⁵ H 3.15 362 23 F F O H CF₃ H Cl H H H CR⁵ H 3.21 386 24 F F O H Me H Cl H H H CR⁵ H 2.75 332 25 F F O H H H Cl H H H CR⁵ H 2.50 318 26 F F O H Me Me Cl H H H CR⁵ H 2.92 346 27 Cl F O Me Me H Cl H H H CR⁵ H 2.84 362 28 F F O Me Me H Cl H H H CR⁵ H 2.68 346 29 F F O H Me H Cl Cl H H CR⁵ H 3.13 366 30 Cl F O cyclobutyl H H Cl H Cl H CR⁵ H 4.39 422 31 F F O cyclobutyl H H Cl H Cl H CR⁵ H 4.19 406 32 Cl F O H CF₃ H Cl H Cl H CR⁵ H 3.89 436 33 Cl F O H Me H Cl H Cl H CR⁵ H 4.39 382 34 Cl F O H H H Cl H Cl H CR⁵ H 4.19 368 35 Cl F O H Me Me Cl H Cl H CR⁵ H 3.89 396 36 F F O H Me H Cl H Cl H CR⁵ H 4.39 366 37 F F O H H H Cl H Cl H CR⁵ H 4.19 352 38 F F O H —CH₂CH₂— Cl H Cl H CR⁵ H 3.89 378 39 F F O H Me Me Cl H Cl H CR⁵ H 4.39 380 40 F F O H CF₃ H Cl H Cl H CR⁵ H 4.19 420 41 Cl F O H —CH₂CH₂— Cl H Cl H CR⁵ H 3.89 394 42 Cl F O Me H H Cl H Cl H CR⁵ H 3.37 382 43 F F O Me H H Cl H Cl H CR⁵ H 3.19 366 44 Cl F S H Me H Cl H Cl H CR⁵ H 3.99 398 45 F F O OMe Me H Cl H Cl H CR⁵ H 3.65 396 46 Cl F O OMe Me H Cl H Cl H CR⁵ H 3.81 412 47 Cl F O H H H Cl H H Cl CR⁵ H 4.39 368 48 Cl F O H —CH₂CH₂— Cl H H Cl CR⁵ H 4.19 394 49 Cl F O H Me Me Cl H H Cl CR⁵ H 3.89 396 50 Cl F O H Me H Cl H H Cl CR⁵ H 4.39 382 51 F F O H —CH₂CH₂— Cl H H Cl CR⁵ H 4.19 378 52 F F O H Me Me Cl H H Cl CR⁵ H 3.89 380 53 F F O H Me H Cl H H Cl CR⁵ H 4.39 366 54 F F O H H H Cl H H Cl CR⁵ H 4.19 352 55 Cl F O Me Me H Cl H H Cl CR⁵ H 3.33 396 56 F F O Me Me H Cl H H Cl CR⁵ H 3.15 380 57 Cl F O Me H H Cl H H Cl CR⁵ H 3.23 382 58 F F O Me H H Cl H H Cl CR⁵ H 3.02 366 59 Cl F O H H H Cl H H H CR⁵ Cl 3.89 368 60 F F O H H H Cl H H H CR⁵ Cl 4.39 352 61 Cl F O Me H H Cl H H H CR⁵ Cl 3.02 382 62 F F O Me H H Cl H H H CR⁵ Cl 2.82 366 63 Cl F O Me Me H Cl H H H CR⁵ Cl 3.25 396 64 F F O Me Me H Cl H H H CR⁵ Cl 3.13 380 65 F F O H H H c-Pr ⁽¹⁾ H H H CR⁵ H 2.78 324 66 Cl F O H H H c-Pr H H H CR⁵ H 2.98 340 67 F F O cyanomethyl H H i-Pr H H H CR⁵ H 2.94 365 68 F F O Et H H i-Pr H H H CR⁵ H 3.42 354 69 F F O i-Pr H H i-Pr H H H CR⁵ H 3.70 368 70 F F O cyclobutyl H H i-Pr H H H CR⁵ H 3.90 380 71 F F O allyl H H i-Pr H H H CR⁵ H 3.66 366 72 F F O Me H H i-Pr H H H CR⁵ H 3.11 340 73 F F O propargyl H H i-Pr H H H CR⁵ H 3.37 364 74 F F O H H H i-Pr H H H CR⁵ H 3.02 326 75 F F S cyclobutyl H H i-Pr H H H CR⁵ H 4.63 396 76 F F O OMe H H i-Pr H H H CR⁵ H 3.37 356 77 Cl F O OMe H H i-Pr H H H CR⁵ H 3.51 372 78 F F O 2,2- H H i-Pr H H H CR⁵ H 3.49 difluoroethyl 79 Cl F O H H H i-Pr H H H CR⁵ H 3.19 342 80 F F O 2,2- H H i-Pr H H Cl CR⁵ H 3.81 difluoroethyl 81 F F O H H H CF₃ H H H CR⁵ H 2.76 352 82 Cl F O H Me H CF₃ H H H CR⁵ H 3.11 382 83 Cl F O H H H CF₃ H H H CR⁵ H 2.96 368 84 F F O H Me H CF₃ H H H CR⁵ H 2.96 366 85 Cl F S H Me H CF₃ H H H CR⁵ H 3.55 398 86 Cl F O 3-thietanyl H H CF₃ H H Cl CR⁵ H 4.08 474 87 F F O 3-thietanyl H H CF₃ H H Cl CR⁵ H 3.92 458 88 F F O cyanomethyl H H CF₃ H H H CR⁵ Cl 2.68 425 89 F F O Me H H CF₃ H H H CR⁵ Cl 2.93 400 90 F F O cyclobutyl H H CF₃ H H H CR⁵ Cl 3.81 440 91 F F O Et H H CF₃ H H H CR⁵ Cl 3.22 414 92 F F O i-Pr H H CF₃ H H H CR⁵ Cl 3.61 428 93 F F O propargyl H H CF₃ H H H CR⁵ Cl 3.05 424 94 F F O allyl H H CF₃ H H H CR⁵ Cl 3.37 426 95 F F O H H H CF₃ H H H CR⁵ F 2.69 370 96 Cl F O H H H CF₃ H H H CR⁵ F 2.86 386 97 F F O cyanomethyl H H trimethyl- H H H CR⁵ H 3.52 395 silyl 98 F F O cyclobutyl H H trimethyl- H H H CR⁵ H 4.61 410 silyl 99 F F O Et H H trimethyl- H H H CR⁵ H 4.09 384 silyl 100 F F O allyl H H trimethyl- H H H CR⁵ H 4.27 396 silyl 101 F F O propargyl H H trimethyl- H H H CR⁵ H 3.93 394 silyl 102 F F O i-Pr H H trimethyl- H H H CR⁵ H 4.37 398 silyl 103 F F O Me H H trimethyl- H H H CR⁵ H 3.78 370 silyl 104 Cl F O Me H H Br H H H CR⁵ H 2.90 392 105 F F O Me H H Br H H H CR⁵ H 2.71 376 106 Cl F O H H H SCF₃ H H H CR⁵ H 3.29 400 107 F F O H H H SCF₃ H H H CR⁵ H 3.11 384 108 F F O H —[CH₂]₄— H CF₃ H H CR⁵ H 3.65 406 109 Cl F O H —[CH₂]₄— H CF₃ H H CR⁵ H 3.80 422 110 F F O H H H H —CH₂CH₂CH₂CH₂— H CR⁵ H 3.25 338 111 Cl F O H H H H —CH₂CH₂CH₂CH₂— H CR⁵ H 3.44 354 112 Cl F O H Me Me H Cl H Cl CR⁵ H 3.73 396 113 Cl F O H H H H Cl H Cl CR⁵ H 3.23 368 114 F F O H Me Me H Cl H Cl CR⁵ H 3.59 380 115 F F O H H H H Cl H Cl CR⁵ H 3.09 352 116 Cl F O Me Me H H Cl H Cl CR⁵ H 3.65 396 117 F F O Me Me H H Cl H Cl CR⁵ H 3.46 380 118 F F S Me Me H H Cl H Cl CR⁵ H 4.24 396 119 F F O H H H H OMe OMe H CR⁵ H 1.79 344 120 Cl F O H H H H OMe OMe H CR⁵ H 1.36 360 121 F F O H —[CH₂]₄— H H CF₃ H CR⁵ H 3.72 406 122 Cl F O H —[CH₂]₄— H H CF₃ H CR⁵ H 3.87 422 123 F F O H H H H H CF₃ H CR⁵ H 2.75 352 124 Cl F O H H H H H CF₃ H CR⁵ H 2.90 368 125 F F O H —CH₂CH₂— H H Cl CF₃ CR⁵ H 3.27 412 126 Cl F O H —CH₂CH₂— H H Cl CF₃ CR⁵ H 3.41 428 127 F F O H H H H H Cl H CR⁵ H 2.55 318 128 Cl F O H H H H H Cl H CR⁵ H 2.70 334 129 F F O H Me H H H cyclohexyl H CR⁵ H 4.34 380 130 Cl F O H —[CH₂]₄— H H OEt H CR⁵ H 3.59 398 131 F F O H —[CH₂]₄— H H OEt H CR⁵ H 3.44 382 132 Cl F O H —[CH₂]₄— H H OMe H CR⁵ H 3.19 384 133 F F O H —[CH₂]₄— H H OMe H CR⁵ H 3.06 368 134 F F O H H H H H OMe H CR⁵ H 2.08 314 135 F F O H H H H H t-Bu ⁽¹⁾ H CR⁵ H 3.42 340 136 Cl F O H H H H H t-Bu H CR⁵ H 3.58 356 137 Cl F O H H —CH₂CH₂— H H H CR⁵ H 2.73 326 138 F F O H H —CH₂CH₂— H H H CR⁵ H 2.57 310 139 Cl F O H H —CH₂CH₂CH₂CH₂— H H H CR⁵ H 3.02 340 140 F F O H H —CH₂CH₂CH₂CH₂— H H H CR⁵ H 2.84 324 141 F F O Me H —CH₂CH₂CH₂CH₂— H H H CR⁵ H 2.92 338 142 Cl F O Me H —CH₂CH₂CH₂CH₂— H H H CR⁵ H 3.09 354 143 Cl F O H H H phenoxy H H H CR⁵ H 3.46 392 144 F F O H H H phenoxy H H H CR⁵ H 3.25 376 145 F F O H H H H phenoxy H H CR⁵ H 3.23 376 146 Cl F O H H H H phenoxy H H CR⁵ H 3.46 392 147 Cl F O 3-oxetanyl H H H phenoxy H H CR⁵ H 3.19 448 148 F F O 3-oxetanyl H H H phenoxy H H CR⁵ H 3.06 432 149 Cl F O Me H H H phenoxy H H CR⁵ H 3.46 406 150 F F O Me H H H phenoxy H H CR⁵ H 3.31 390 151 Cl F O H H H H H phenoxy H CR⁵ H 3.37 392 152 F F O H H H H H phenoxy H CR⁵ H 3.23 376 153 Cl F O Me Me H H H phenoxy H CR⁵ H 3.76 420 154 F F O Me Me H H H phenoxy H CR⁵ H 3.59 404 155 Cl F O Me H H H H phenoxy H CR⁵ H 3.48 406 156 F F O Me H H H H phenoxy H CR⁵ H 3.33 390 157 Cl F O Me H H H H 4-chloro H CR⁵ H 3.96 440 phenoxy 158 F F O Me H H H H 4-chloro H CR⁵ H 3.81 424 phenoxy 159 Cl F O H Me H H H benzyloxy H CR⁵ H 3.58 420 160 Cl F O H H H H H benzyloxy H CR⁵ H 3.37 406 161 F F O H H H H H benzyloxy H CR⁵ H 3.23 390 162 F F O H Me H H H benzyloxy H CR⁵ H 3.41 404 163 F F O H H H phenyl H H H CR⁵ H 3.21 360 164 Cl F O H H H phenyl H H H CR⁵ H 3.39 376 165 Cl F O H H H H phenyl H H CR⁵ H 3.33 376 166 F F O H H H H phenyl H H CR⁵ H 3.19 360 167 Cl F O H Me H H H phenyl H CR⁵ H 3.62 390 168 Cl F O H H H H H phenyl H CR⁵ H 3.35 376 169 F F O H Me H H H phenyl H CR⁵ H 3.46 374 170 F F O H H H H H phenyl H CR⁵ H 3.21 360 171 Cl F O H —[CH₂]₄— H H H H N — 1.30 355 172 F F O H —[CH₂]₄— H H H H N — 1.13 339 173 Cl F O Me H H H Cl H H N — 2.01 349 174 F F O Me H H H Cl H H N — 1.84 333 175 F F O H Me H Cl H CF₃ H N — 3.19 401 176 F F O H H H Cl H CF₃ H N — 2.76 387 177 Cl F O H Me H Cl H CF₃ H N — 3.48 417 178 Cl F O H H H Cl H CF₃ H N — 3.08 403 179 F F O Me H H Cl H Cl H N — 2.53 367 180 Cl F O Me H H Cl H Cl H N — 2.73 383 181 F F O OMe H H Cl H Cl H N — 2.73 383 182 Cl F O OMe H H Cl H Cl H N — 2.88 399 183 F F O cyclopentyl H H Cl H Cl H N — 3.85 421 184 Cl F O cyclopentyl H H Cl H Cl H N — 4.11 437 185 F F O Me Me H Cl H Cl H N — 2.92 381 186 Cl F O Me Me H Cl H Cl H N — 3.11 397 187 F F O cyclopentyl Me H Cl H Cl H N — 4.44 435 188 Cl F O cyclopentyl Me H Cl H Cl H N — 4.67 451 189 Cl F O cyclopentyl H H Cl H CF₃ H N — 4.21 471 190 F F O cyclopentyl H H Cl H CF₃ H N — 3.96 455 191 Cl F O H Et H Cl H Cl H CR⁵ H 3.79 396 192 F F O H Et H Cl H Cl H CR⁵ H 3.61 380 Note ⁽¹⁾ i-Pr: isopropyl; c-Pr: cyclopropyl; t-Bu: tertiobutyl

The following examples illustrate in a non limiting manner the preparation and efficacy of the compounds of formula (I) according to the invention.

Synthesis of 5-chloro-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylic acid (example IIIa-1)

In a 500 ml flask, 6.0 g (31 mmol) of 5-chloro-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carbaldehyde are added to 30 ml of toluene. A solution of 2.4 g (62 mmol) of sodium hydroxide in 6 ml of water is added to the reaction mixture, followed by 103 ml of a 30% solution of hydrogen peroxide in water, whilst keeping the temperature below 37° C. After the end of the addition, the reaction mixture is stirred at 50° C. for 7 hours. Once the reaction mixture is back to room temperature, the two phases are separated and the organic phase is extracted with 100 ml of water. The combined aqueous phases are acidified to pH 2 with aqueous hydrochloric acid. The resulting white precipitate is filtered, washed twice with 20 ml of water, and dried to yield 3.2 g of 5-chloro-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylic acid as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm: 3.78 (s, 3H); 7.12 (t, 1H, JHF=53.60 Hz); 13.19 (s, 1H); IR (KBr): 1688 cm⁻¹ (C═O); 2200-3200 cm⁻¹ broad (hydrogen bond).

Synthesis of 5-chloro-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carbonyl chloride (example IIIb-1)

3.2 g of 5-chloro-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylic acid and 44.3 ml of thionyl chloride are refluxed for 5 hours. After cooling down, the reaction mixture is evaporated under vacuum to yield 3.5 g of 5-chloro-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carbonyl chloride as a yellow oil. ¹H NMR (400 MHz, CHCl₃-d₆) δ ppm: 3.97 (s, 3H); 7.00 (t, J=52.01 Hz, 1 H); IR (TQ): 1759 and 1725 cm⁻¹ (C═O).

Synthesis of 3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carbonyl fluoride (example IIIc-1)

To a dried solution of 4.0 g (70 mmol) of potassium fluoride in 21 ml of tetrahydrothiophene-1,1-dioxide is added a solution of 5.0 g (22 mmol) of 5-chloro-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carbonyl chloride in 15 ml of toluene at 100° C. The resulting reaction mixture is stirred at 190-200° C. for 22 hours. Distillation under vacuum yields 8 g of a solution (0.25 M) of 3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carbonyl fluoride in tetrahydrothiophene-1,1-dioxide. ¹H NMR (250 MHz, CHCl₃-d₆) δ ppm: 3.87 (s, 3H); 6.79 (t, J=53.75 Hz, 1 H); ¹⁹F NMR (250 MHz, CHCl₃-d₆) δ ppm: 45.37 (s, COF); −117.5 (d, J=28.2 Hz); −131.6 (m).

Synthesis of 3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxylic acid (example IIId-1)

To 400 ml of a 1N sodium hydroxide aqueous solution, is added dropwise 67.5 g of a solution (0.1 M) of 3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carbonyl fluoride in tetrahydro-thiophene-1,1-dioxide. The temperature is kept below 20° C. during the addition. After 2 hours of stirring at room temperature, the reaction mixture is carefully acidified to pH 2 with concentrated aqueous hydrochloric acid. The resulting white precipitate is filtered, washed with water, and dried to yield 6 g of 3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxylic acid as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm: 3.90 (s, 3H); 7.22 (t, 1H, J_(HF)=53.55 Hz); 13.33 (s, 1H).

Synthesis of 3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carbonyl chloride (example IIIe-1)

9.1 g of 3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxylic acid and 75.5 ml of thionyl chloride are refluxed for 1.5 hours. After cooling down, the reaction mixture is evaporated under vacuum to yield 10 g of 3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carbonyl chloride as a yellow oil. GC-MS; observed m/z: Molecular ion: (M⁺)=212; fragments: (M⁺.-Cl)=177 and (M⁺.-F)=193.

GENERAL PREPARATION EXAMPLE 2 Preparation of Amide of Formula (I) on Chemspeed™ Apparatus

In a 13 ml Chemspeed™ vial is distributed 4 ml of a 0.15 M solution of the amine (II) (0.60 mmol) in dichloromethane followed by 0.72 mmol of triethylamine. At a rate of 1 ml/mn, 2 ml of a 0.30 M solution of the acyl chloride (IIIb) or (IIIe) (0.60 mmol) are added and the mixture is then stirred at room temperature overnight. 1 ml of water is then added and the mixture is poured over a basic alumina cartridge (2 g) and eluted with dichloromethane. The solvents are removed and the crude amide derivative is analyzed by LCMS and NMR. Insufficiently pure compounds are further purified by preparative LCMS.

GENERAL PREPARATION EXAMPLE 3 Thionation of Amide of Formula (I) on Chemspeed™ Apparatus

In a 13 ml Chemspeed™ vial is weighted 0.27 mmol of phosphorous pentasulfide (P₂S₅). 3 ml of a 0.18 M solution of the amide (I) (0.54 mmol) in dioxane are added and the mixture is heated at reflux for two hours. The temperature is then cooled to 80° C. and 2.5 ml of water are added. The mixture is heated at 80° C. for one more hour. 2 ml of water are then added and the reaction mixture is extracted twice by 4 ml of dichloromethane. The organic phase is deposited on a basic alumina cartridge (2 g) and eluted twice by 8 ml of dichloromethane. The solvents are removed and the crude thioamide derivative is analyzed by LCMS and NMR. Insufficiently pure compounds are further purified by preparative LCMS.

EXAMPLE A In Vivo Preventive Test on Sphaerotheca fuliginea (Cucumber)

Solvent: 49 parts by weight of N,N-dimethylformamide

Emulsifier: 1 part by weight of alkylarylpolyglycolether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for preventive activity, young plants are sprayed with the preparation of active compound at the stated rate of application. After the spray coating has dried on, the plants are inoculated with an aqueous spore suspension of Sphaerotheca fuliginea. The plants are then placed in a greenhouse at approximately 23° C. and a relative atmospheric humidity of approximately 70%.

The test is evaluated 7 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed. Under these conditions, good (at least 75% of disease control) to total protection (100% of disease control) is observed at a dose of 500 ppm ppm of active ingredient with the following compounds from table A:

TABLE A Example Efficacy 12 95 13 90 15 83 17 94 18 90 19 84 20 94 22 80 24 89 26 88 28 85 29 93 32 95 33 96 35 86 36 93 38 89 39 95 40 83 45 100 49 94 50 98 52 80 53 95 55 83 56 95 65 85 68 100 70 100 71 91 72 98 73 98 74 95 75 100 76 93 78 93 82 94 84 90 90 100 91 95 98 96 99 95 103 91 108 85 112 95 116 75 117 95 118 95 125 100 162 88 169 89 175 95 177 93 191 100 192 100

Under the same conditions, high (at least 90%) protection at a dose of 500 ppm of active ingredient with compound 29, whereas medium (less than 60%) protection is observed with the compound of example 1.043 disclosed in patent application WO-2009/024342 as in table A2.

TABLE A2 Example dose (ppm) Efficacy 29 from this invention 500 93 1.043 from WO2009/024342 500 55 Example 1.043 disclosed in international patent WO-2009/024342 corresponds to N-[1-(2,3-dichlorophenyl)ethyl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide. These results show that the compounds according to the invention have a better biological activity than the structurally closest compounds disclosed in WO-2009/024342.

EXAMPLE B In Vivo Preventive Test on Alternaria Solani (Tomato)

Solvent: 49 parts by weight of N,N-dimethylformamide

Emulsifier: 1 part by weight of alkylarylpolyglycolether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for preventive activity, young plants are sprayed with the preparation of active compound at the stated rate of application. One day after this treatment, the plants are inoculated with an aqueous spore suspension of Alternaria solani. The plants remain for one day in an incubation cabinet at approximately 22° C. and a relative atmospheric humidity of 100%. Then the plants are placed in an incubation cabinet at approximately 20° C. and a relative atmospheric humidity of 96%.

The test is evaluated 7 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control while an efficacy of 100% means that no disease is observed.

Under these conditions, good (at least 70% of disease control) to total protection (100% of disease control) is observed at a dose of 500 ppm of active ingredient with the following compounds from table B:

TABLE B Example Efficacy 1 95 2 93 12 90 13 95 15 95 16 80 17 80 18 95 19 90 20 95 23 89 24 94 26 94 27 80 28 95 29 94 30 90 33 95 36 94 37 94 38 94 39 70 40 94 41 80 43 90 44 100 45 100 46 100 50 95 51 94 53 94 54 89 55 95 56 100 65 90 68 80 70 90 71 95 72 95 73 95 74 95 76 94 78 100 81 90 82 100 83 90 84 100 85 95 88 80 89 95 90 95 91 100 98 70 99 95 100 80 101 70 103 90 105 95 107 80 110 94 112 80 113 90 115 94 116 95 117 100 118 100 121 70 127 90 129 95 137 89 138 94 139 100 140 94 141 80 144 89 145 90 147 70 148 80 150 70 152 89 153 90 154 95 156 89 158 95 161 94 162 100 166 78 167 95 169 94 170 94 175 95 176 70 177 90 179 90 180 80 181 80 185 100 191 95 192 95

Under the same conditions, excellent (at least 95%) protection to high (at least 90%) protection is observed at a dose of 500 ppm and 100 ppm of active ingredient with compound 129, whereas good (at least 80%) protection to no protection is observed with the compound of example 1.029 disclosed in patent application WO-2009/024342 as in table B2.

TABLE B2 Example dose (ppm) Efficacy 129 from this invention 500 95 100 90 1.029 from WO2009/024342 500 89 100 0

Example 1.029 disclosed in international patent WO-2009/024342 corresponds to N-[1-(4-cyclohexylphenyl)ethyl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide.

These results show that the compounds according to the invention have a better biological activity than the structurally closest compounds disclosed in WO-2009/024342.

Under the same conditions, high (at least 90%) protection to excellent (at least 95%) protection is observed at a dose of 500 ppm active ingredient with compound 28 and compound 30 without any plant damages, whereas 100% of plant damages is observed with the compound of example 89 disclosed in patent application WO-2009/016221 as in table B3.

TABLE B3 Example dose (ppm) Efficacy 28 from this invention 500 95 30 from this invention 500 90 89 from WO2009/016221 500 — ^((a)) note ^((a)) 100% of plant damages

Example 89 disclosed in international patent WO-2009/016221 corresponds to N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-N-[1-(1-naphthyl)ethyl]-1H-pyrazole-4-carboxamide.

These results show that the compounds according to the invention have a better biological activity than the structurally closest compounds disclosed in WO-2009/016221.

Under the same conditions, high (at least 90%) protection to total protection is observed at a dose of 500 ppm active ingredient with compound 43 and compound 45 without any plant damages, whereas poor (less than 30%) protection to 90% of plant damages is observed with the compounds of example 236 and example 263 disclosed in patent application WO-2007/087906 as in table B4.

TABLE B4 Example dose (ppm) Efficacy 43 from this invention 500 90 45 from this invention 500 100  236 from WO2007/087906 500 30 263 from WO2007/087906 500 — ^((b)) note ^((b)) 90% of plant damages

Example 236 disclosed in international patent WO-2007/087906 corresponds to N-cyclopropyl-N-(2,4-dichlorobenzyl)-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide and example 263 disclosed in international patent WO-2007/087906 corresponds to N-cyclopropyl-N-[1-(2,4-dichlorophenyl)ethyl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide.

These results show that the compounds according to the invention have a better biological activity than the structurally closest compounds disclosed in WO-2007/087906.

EXAMPLE C In Vivo Preventive Test on Pyrenophora teres (Barley)

Solvent: 49 parts by weight of N,N-dimethylacetamid

Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for preventive activity, young plants are sprayed with the preparation of active compound at the stated rate of application. One day after this treatment, the plants are inoculated with an aqueous spore suspension of Pyrenophora teres. The plants remain for 48 hours in an incubation cabinet at 22° C. and a relative atmospheric humidity of 100%. Then the plants are placed in a greenhouse at a temperature of approximately 20° C. and a relative atmospheric humidity of approximately 80%.

The test is evaluated 7-9 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control while an efficacy of 100% means that no disease is observed.

Under these conditions, good (at least 70% of disease control) to total protection (100% of disease control) is observed at a dose of 500 ppm of active ingredient with the following compounds from table C:

TABLE C Example Efficacy 1 95 2 94 5 89 6 78 12 100 13 95 15 95 16 100 17 100 18 100 20 95 24 100 27 100 28 100 29 100 30 100 31 100 33 100 36 100 38 95 39 95 40 95 43 100 44 100 45 100 46 100 50 95 51 80 53 95 55 100 56 100 61 100 62 100 64 95 65 94 67 90 68 100 70 100 71 95 72 100 73 100 74 100 75 100 78 100 79 95 80 100 82 95 84 100 85 100 87 95 89 100 90 100 91 95 92 70 93 95 94 80 99 95 101 80 103 70 104 78 105 94 106 90 107 100 108 94 110 80 112 95 113 80 115 90 116 100 117 100 118 100 121 94 123 70 125 95 126 95 127 90 128 80 129 100 131 94 133 95 135 95 139 70 140 80 141 100 142 95 148 95 149 70 150 100 152 95 153 80 154 100 156 90 157 90 158 100 159 95 161 90 162 100 166 80 167 90 169 100 170 95 174 75 175 100 177 100 179 100 180 100 181 100 182 95 185 95 187 90 188 95 191 100 192 100

Under the same conditions, good (at least 70%) protection and excellent (at least 95%) protection is observed at a dose of 500 ppm of active ingredient with compound 123 and compound 135, whereas no protection or poor (less than 30%) protection is observed with the compounds of example 145 and example 146 disclosed in patent application CN1188764 as in table C2.

TABLE C2 Example dose (ppm) Efficacy 123 from this invention 500 70 135 from this invention 500 95 145 from CN1188764 500 0 146 from CN1188764 500 20

Example 145 disclosed in international patent CN1188764 corresponds to 5-chloro-1,3-dimethyl-N-[4-(trifluoromethyl)benzyl]-1H-pyrazole-4-carboxamide and example 146 disclosed in international patent CN1188764 corresponds to N-(4-tert-butylbenzyl)-5-chloro-1,3-dimethyl-1H-pyrazole-4-carboxamide.

These results show that the compounds according to the invention have a better biological activity than the structurally closest compounds disclosed in CN1188764.

Under the same conditions, high (at least 80%) protection is observed at a dose of 500 ppm of active ingredient with compound 127 and compound 128, whereas no protection is observed with the compound of example 24 disclosed in J. Korean Agric. Chem. Soc. (1992), 35(2), 87-91 as in table C3.

TABLE C3 Example dose (ppm) Efficacy 127 from this invention 500 90 128 from this invention 500 80 24 from J. Korean. Agric. 500 0 Chem. Soc (1992), 35, 87

Example 24 disclosed in J. Korean Agric. Chem. Soc. (1992), 35(2), 87-91 corresponds to 5-chloro-N-(4-chlorobenzyl)-1,3-dimethyl-1H-pyrazole-4-carboxamide

These results show that the compounds according to the invention have a better biological activity than the structurally closest compounds disclosed in J. Korean Agric. Chem. Soc. (1992), 35(2), 87-91.

EXAMPLE D In Vivo Preventive Test on Leptosphaeria nodorum (Wheat)

Solvent: 49 parts by weight of N,N-dimethylacetamide

Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for preventive activity, young plants are sprayed with a preparation of active compound at the stated rate of application. One day after this treatment, the plants are inoculated with an aqueous spore suspension of Leptosphaeria nodorum. The plants remain for 48 hours in an incubation cabinet at 22° C. and a relative atmospheric humidity of 100%. Then the plants are placed in a greenhouse at a temperature of approximately 22° C. and a relative atmospheric humidity of approximately 90%.

The test is evaluated 7-9 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.

Under these conditions, good (at least 70%) to excellent protection (at least 95%) is observed at a dose of 500 ppm of active ingredient with the following compounds from table D:

TABLE D Example Efficacy 18 95 30 90 31 80 39 90 44 89 45 95 56 70 72 78 74 80 76 89 79 94 117 70 118 70 135 75 136 70 141 95 154 70 179 70 181 70 185 95 187 80

EXAMPLE E In Vivo Preventive Test on Puccinia triticina (Wheat)

Solvent: 49 parts by weight of N,N-dimethylacetamide

Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for preventive activity, young plants are sprayed with the preparation of active compound or active compound combination at the stated rate of application.

After the spray coating has been dried, the plants are sprayed with a spore suspension of Puccinia triticina. The plants remain for 48 hours in an incubation cabinet at approximately 20° C. and a relative atmospheric humidity of approximately 100%.

The plants are placed in the greenhouse at a temperature of approximately 20° C. and a relative atmospheric humidity of approximately 80%.

The test is evaluated 8 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.

Under these conditions, good (at least 70%) to total protection is observed at a dose of 500 ppm of active ingredient with the following compounds from table E:

TABLE E Example Efficacy 29 80 68 70 90 95 98 95 99 100 100 80 101 90 106 80 117 70 126 78 141 95 180 80 181 70 184 70 185 90

Under the same conditions, good (at least 80%) protection at a dose of 500 ppm of active ingredient with compound 29, whereas no protection is observed with the compound of example 1.043 disclosed in patent application WO-2009/024342 as in table E2.

TABLE E2 Example dose (ppm) Efficacy 29 from this invention 500 80 1.043 from WO2009/024342 500 0

Example 1.043 disclosed in international patent WO-2009/024342 corresponds to N-[1-(2,3-dichlorophenyl)ethyl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide.

These results show that the compounds according to the invention have a better biological activity than the structurally closest compounds disclosed in WO-2009/024342.

EXAMPLE F In Vivo Preventive Test on Septoria tritici (Wheat)

Solvent: 49 parts by weight of N,N-dimethylacetamide

Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for preventive activity, young plants are sprayed with the preparation of active compound or active compound combination at the stated rate of application.

After the spray coating has been dried, the plants are sprayed with a spore suspension of Septoria tritici. The plants remain for 48 hours in an incubation cabinet at approximately 20° C. and a relative atmospheric humidity of approximately 100% and afterwards for 60 hours at approximately 15° C. in a translucent incubation cabinet at a relative atmospheric humidity of approximately 100%.

The plants are placed in the greenhouse at a temperature of approximately 15° C. and a relative atmospheric humidity of approximately 80%.

The test is evaluated 21 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.

Under these conditions, good (at least 70%) to total protection is observed at a dose of 500 ppm of active ingredient with the following compounds from table F:

TABLE F Example Efficacy 29 88 68 100 72 90 90 100 141 70 185 100

EXAMPLE G In Vivo Preventive Test on Blumeria graminis (Barley)

Solvent: 49 parts by weight of N,N-dimethylacetamide

Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for preventive activity, young plants are sprayed with the preparation of active compound or active compound combination at the stated rate of application.

After the spray coating has been dried, the plants are dusted with spores of Blumeria graminis f.sp. hordei.

The plants are placed in the greenhouse at a temperature of approximately 18° C. and a relative atmospheric humidity of approximately 80% to promote the development of mildew pustules.

The test is evaluated 7 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.

Under these conditions, total protection is observed at a dose of 500 ppm of active ingredient with the following compounds from table G:

TABLE G Example Efficacy 68 100 72 100 90 100 141 100 185 100 

The invention claimed is:
 1. A compound of formula (I)

wherein Y represents CR⁵ or N; T represents O or S; X¹ and X² which can be the same or different, represent a chlorine or a fluorine atom; Z¹ represents a hydrogen atom, substituted or non substituted C₁-C₈-alkyl; substituted or non substituted C₁ -C₈-alkoxy; substituted or non substituted C₂-C₈-alkenyl; substituted or non substituted C₂-C₈-alkynyl; substituted or non substituted C₄-C₇-cycloalkyl; substituted or non substituted C₃-C₇-cycloalkyl-C₁-C₈-alkyl; substituted or non substituted 3-oxetanyl; or substituted or non substituted 3-thietanyl; Z² and Z³, which can be the same or different, represent a hydrogen atom; substituted or non substituted C₁-C₈-alkyl; substituted or non substituted C₂-C₈-alkenyl; substituted or non substituted C₂-C₈-alkynyl; cyano; isonitrile; nitro; a halogen atom; substituted or non substituted C₁ -C₈-alkoxy; substituted or non substituted C₂-C₈-alkenyloxy; substituted or non substituted C₂-C₈-alkynyloxy; substituted or non substituted C₃-C₇-cycloalkyl; substituted or non substituted C₁-C₈-alkylsulfanyl; substituted or non substituted C₁-C₈-alkylsulfonyl; substituted or non substituted C₁-C₈alkylsulfinyl; amino; substituted or non substituted C₁-C₈-alkylamino; substituted or non substituted di-C₁-C₈-alkylamino; substituted or non substituted C₁-C₈-alkoxycarbonyl; substituted or non substituted C₁-C₈-alkylcarbamoyl; substituted or non substituted di-C₁-C₈-alkylcarbamoyl; or substituted or non substituted N-C₁-C₈-alkyl-C₁-C₈-alkoxy-carbamoyl; or Z³ and R¹ together with the consecutive carbon atoms to which they are linked form a substituted or non substituted 5-, 6- or 7-membered, partly saturated, carbo- or hetero-cycle comprising up to 3 heteroatoms and Z² is as herein described; or Z² and Z³ together with the carbon atom to which they are linked form a substituted or non substituted C₃-C₇ cycloalkyl; R¹, R², R³, R⁴and R⁵, which can be the same or different, represent a hydrogen atom; a halogen atom; nitro; cyano; isonitrile; hydroxyl; sulfanyl; amino; pentafluoro-λ⁶-sulfanyl; substituted or non substituted C₁-C₈-alkyl; C-C₈-halogenoalkyl comprising up to 9 halogen atoms which can be the same or different; substituted or non substituted C₁-C₈-alkylamino; substituted or non substituted di-C₁-C₈-alkylamino ; substituted or non substituted C₁-C₈-alkoxy; C₁-C₈-halogenoalkoxy comprising up to 9 halogen atoms which can be the same or different; C₁-C₈-alkoxy-C₁-C₈-alkyl; substituted or non substituted C₁-C₈-alkylsulfanyl; C₁-C₈-halogenoalkylsulfanyl comprising up to 9 halogen atoms which can be the same or different; substituted or non substituted C₂-C₈-alkenyl; C₂-C₈-halogenoalkenyl comprising up to 9 halogen atoms which can be the same or different; substituted or non substituted C₂-C₈-alkynyl; C₂-C₈-halogenoalkynyl comprising up to 9 halogen atoms which can be the same or different; substituted or non substituted C₂-C₈-alkenyloxy; C₂-C₈-halogenoalkenyloxy comprising up to 9 halogen atoms which can be the same or different; substituted or non substituted C₂-C₈-alkynyloxy; C₂-C₈-halogenoalkynyloxy comprising up to 9 halogen atoms which can be the same or different; substituted or non substituted C₃-C₇-cycloalkyl; C₃-C₇-halogenocycloalkyl comprising up to 9 halogen atoms which can be the same or different; substituted or non substituted C₃-C₇-cycloalkyl-C₁-C₈-alkyl; substituted or non substituted C₃-C₇-cycloalkyl-C₂-C₈-alkenyl; substituted or non substituted C₃-C₇-cycloalkyl-C₂-C₈-alkynyl; substituted or non substituted C₃-C₇-cycloalkyl-C₃-C₇-cycloalkyl; substituted or non substituted C₁-C₈-alkyl-C₃-C₇-cycloalkyl; formyl; formyloxy; formylamino; carboxy; carbamoyl; N-hydroxycarbamoyl; carbamate; (hydroxyimino)-C₁-C₈-alkyl; substituted or non substituted C₁-C₈-alkylcarbonyl; C₁-C₈-halogenoalkylcarbonyl comprising up to 9 halogen atoms which can be the same or different; substituted or non substituted C₁-C₈-alkylcarbamoyl; substituted or non substituted di-C₁-C₈-alkylcarbamoyl; N-(substituted or non substituted C₁-C₈-alkyloxy)carbamoyl; substituted or non substituted C₁-C₈-alkoxycarbamoyl; N -(substituted or non substituted C₁-C₈-alkyl)-(substituted or non substituted C₁-C₈-alkoxy)-carbamoyl; substituted or non substituted C₁-C₈-alkoxycarbonyl; C₁-C₈-halogenoalkoxycarbonyl comprising up to 9 halogen atoms which can be the same or different; substituted or non substituted C₁-C₈-alkylaminocarbonyl; di- substituted or non substituted C₁-C₈-alkylaminocarbonyl; substituted or non substituted C₁-C₈-alkylcarbonyloxy; C₁-C₈-halogenoalkylcarbonyloxy comprising up to 9 halogen atoms which can be the same or different; substituted or non substituted C₁-C₈-alkylcarbonylamino; C₁-C₈-halogenoalkylcarbonylamino comprising up to 9 halogen atoms which can be the same or different; substituted or non substituted C₁-C₈-alkylaminocarbonyloxy; substituted or non substituted di-C₁-C₈-alkylaminocarbonyloxy; substituted or non substituted C₁-C₈-alkyloxycarbonyloxy; substituted or non substituted C₁-C₈-alkylsulfinyl; C₁-C₈-halogenoalkylsulfinyl comprising up to 9 halogen atoms which can be the same or different; substituted or non substituted C₁-C₈-alkylsulfonyl; C₁-C₈-halogenoalkylsulfonyl comprising up to 9 halogen atoms which can be the same or different; substituted or non substituted C₁-C₈-alkoxyimino; (C₁-C₈-alkoxyimino)-C₁-C₈-alkyl; substituted or non substituted (C₁ -C₈-alkenyloxyimino)-C -C₈-alkyl; (C_(I) -C₈-alkynyloxyim ino)-C₁ -C ₈-alkyl; a (benzyloxyimino)-C₁-C₈-alkyl; tri(substituted or non substituted C_(I)-C₈-alkyOsilyl; tri(substituted or non substituted C₁-C₈-alkyl)silyl-C₁-C₈-alkyl; benzyloxy which can be substituted by up to 5 groups Q; benzylsulfanyl which can be substituted by up to 5 groups Q; benzylamino which can be substituted by up to 5 groups Q; aryl which can be substituted by up to 7 groups Q; aryloxy which can be substituted by up to 7 groups Q; arylamino which can be substituted by up to 7 groups Q; arylsulfanyl which can be substituted by up to 7 groups Q; aryl-C₁-C₈alkyl which can be substituted by up to 7 groups Q; aryl-C₂-C₈-alkenyl which can be substituted by up to 7 groups Q; aryl-C₂-C₈-alkynyl which can be sub.stituted by up to 7 groups Q; pyridinyl which can be substituted by up to 4 groups Q; pyridinyloxy which can be substituted by up to 4 groups Q; aryl-C₃-C₇-cycloalkyl which can be substituted by up to 7 groups Q; or two vicinal substituents R together with the consecutive carbon atoms to which they are linked form a substituted or non substituted 5- or 6-membered, saturated, carbo- or hetero-cycle comprising up to 3 heteroatoms and the other substituents R are as herein-described; or R¹ and Z³ together with the consecutive carbon atoms to which they are linked form a substituted or non substituted 5-, 6- or 7-membered, partly saturated, carbo- or hetero-cycle comprising up to 3 heteroatoms, and R² to R⁵ are as herein-described; Q, which can be the same or different, represents a halogen atom; cyano; nitro; C₁-C₈-alkyl; C₁-C₈alkoxy; C₁-C₈-alkylsulfanyl; C₁-C₈-halogenoalkyl comprising up to 9 halogen atoms which can be the same or different; C₁-C₈-halogenoalkoxy comprising up to 9 halogen atoms which can be the same or different; tri(C₁-C₈)alkylsilyl or tri(C₁-C₈)alkylsilyl-C₁-C₈-alkyl; as well as salts, N-oxides, metal complexes, metalloid complexes and optically active or geometric isomers thereof.
 2. A compound according to claim 1 wherein Y represents CR⁵.
 3. A compound according to claim 1 wherein Y represents N.
 4. A compound according to claim 1 wherein T represents O.
 5. A compound according to claim 1 wherein X¹ represents a fluorine atom.
 6. A compound according to claim 1 wherein X² represents a fluorine atom.
 7. A compound according to claim 1 wherein Z¹ represents a hydrogen atom.
 8. A compound according to claim 1 wherein Z¹ represents a methyl or an ethyl.
 9. A compound according to claim 1 wherein Zhu 1 represents an unsubstituted cyclobutyl.
 10. A compound according to claim 1 wherein Z² and Z³ independently represent a hydrogen atom or a methyl.
 11. A compound according to claim 10 wherein Z² represents a hydrogen atom and Z³ represents a hydrogen atom or a methyl.
 12. A compound according to claim 1 wherein R¹, R², R³, R⁴and R⁵, which can be the same or different, represent a hydrogen atom; a halogen atom; substituted or non substituted C₁-C₈-alkyl; C₁-C₈-halogenoalkyl comprising up to 9 halogen atoms which can be the same or different; substituted or non substituted C₃-C₇-cycloalkyl; tri(C₁-C₈-alkyl)silyl; or substituted or non substituted C₁-C₈-alkylsulfanyl.
 13. A compound according to claim 12 wherein the substituent R¹ represents a halogen atom; C₁-C₈-alkyl; C₁-C₈-halogenoalkyl comprising up to 9 halogen atoms which can be the same or different; C₃-C₇-cycloalkyl; tri(C₁-C₈-alkyl)silyl or C₁-C₈-halogenoalkylsulfanyl comprising up to 9 halogen atoms which can be the same or different.
 14. A compound according to claim 1 wherein the substitutents R¹and R⁵, which can be the same or different, represent a halogen atom; C₁-C₃-alkyl; C ₁-C₈-halogenoalkyl comprising up to 9 halogen atoms which can be the same or different; C₃-C₇-cycloalkyl; tri(C₁-C₈-alkyl)silyl or C₁-C₈-halogenoalkylsulfanyl comprising up to 9 halogen atoms which can be the same or different.
 15. A fungicide composition comprising, as an active ingredient, an effective amount of a compound of formula (I) according to claim 1 and an agriculturally acceptable support, carrier or filler.
 16. A method for controlling phytopathogenic fungi of crops, characterized in that an agronomically effective and substantially non-phytotoxic quantity of a compound according to claim 1 is applied to the soil where plants grow or are capable of growing, to the leaves and/or the fruit of plants or to the seeds of plants.
 17. A method for controlling phytopathogenic fungi of crops, characterized in that an agronomically effective and substantially non-phytotoxic quantity of a fungicide composition according to claim 15 is applied to the soil where plants grow or are capable of growing, to the leaves and/or the fruit of plants or to the seeds of plants. 